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Study  Year  Case ascertainment  Design  Prevalence  Incidence 
















































































































































Study  Design  Comparison  RR (95% CI) of gout 
Bhole, De Vera et al. 2010    Framingham Heart Cohort Study  Diuretic vs. placebo  Men ‐ 3.41 (2.38, 4.89), women ‐ 
2.39 (1.53, 3.74) 
Mikuls, Farrar et al. 2005a   GPRD cohort study  Diuretics vs. placebo  1.72 (1.67, 1.76) 
Choi, Athinson et al. 2005  Cohort  Diuretic vs. placebo  1.77 (1.42, 2.20) 
Grodzicki, Palmer et al. 1997  Cohort  Diuretic vs. placebo  1.59 (0.78, 3.20) 
Gurwitz, Kalish et al. 1997  Cohort  Thiazide vs. placebo  1.99 (1.21, 3.26) 
Lin, Lin et al. 2000b  Cohort  Diuretic vs. placebo  6.47 (2.03, 8.80) 
Hanly, Skedgel et al. 2009  Matched case control  Diuretic vs. placebo  2.80 (2.60, 3.00) 































































































































































































The  earliest  reported  use  of  colchine  was  by  the  Byzantine  physician  Alexander  of  Tralles 
(Copeman 1964).  An alkaloid derived from the autumn crocus (Colchicum autumnale), colchicine 
acts  by  inhibiting  neutrophil  influx  and migration  through  its  interaction  with  E  selectins  on 
endothelial cells  (Cronstein, Terkeltaub 2006). A  randomised placebo controlled  trial concluded 
that  low dose colchicine  (cumulative dose of 1.8 mg  in 24 hours) had equal efficacy and better 
side effect profile  (diarrhoea  and  vomiting)  compared  to higher dose of 4.8 mg over 24 hours 






At present  there  is no evidence  to  suggest  the  superiority of one NSAID over  another or over 




not  recommended  due  to  high  risk  of  gastrointestinal  toxicity  (Sutaria,  Katbamna  et  al.  2006;  







(Khanna, Fitzgerald et al. 2012).   Oral prednisolone 30  to 35 mg  for  five days  is as effective as 
NSAIDS  (Man, Cheung et  al. 2007;  Janssens,  Janssen et  al. 2008).   Based on evidence  from  an 
uncontrolled  trial  (Fernandez, Noguera et al. 1999), a  fast and effective relief of pain and  intra‐
articular  hypertension  (in  addition  to  aiding  diagnosis  through  aspiration  of  synovial  fluid  and 
identification  of MSU  crystals) may  be  provided  by  intra  articular  injection  of  corticosteroid, 
particularly when  the  inflammation  is mono  or  oligoarticular  (Khanna,  Fitzgerald  et  al.  2012).  
Although  limited  by  expense  and  lack  of  license  to  be  used  in  gout  in  the  UK,  when  above 
treatments are contra‐indicated or impractical, biologic drugs may be considered (Rees, Hui et al. 
2014).  Rilonacept  (soluble  receptor  fragment  fusion  protein  which  inhibits  IL  1α  and  β), 











by the US  food and Drug Administration  (FDA)  (Terkeltaub 2003).   Allopurinol  is an analogue of 
the purine bases hypoxanthine and xanthine, and binds competitively to xanthine oxidase thereby 
preventing  the  conversion  of  xanthine  to  uric  acid  (Murrell,  Rapeport  1986).    The  dose  of 
allopurinol can be  titrated  (usually  in 100 mg  increments, with a maximum dose of 900 mg per 
day)  to  reduce  the  concentration  of  SUA  below  the  saturation  threshold  (6  mg/dL)  which 
facilitates  the dissolution of pre‐existing  tophi and prevents progression  to  irreversible cartilage 
and bone damage (Terkeltaub 2003).   
 
Those who  are  intolerant  to  allopurinol  (side‐effects  are  rare  but  can  be  severe  and  include 

















with  repeated  infusions  (Ganson, Kelly et al. 2006).     Other medications with modest uricosuric 
effects are  losartan, vitamin c and fenofibrate, all of which are used as adjunctive treatments  in 
gout  as  they  are unlikely  to  achieve  therapeutic  target  level of uric  acid on  their own  (Stamp, 
O'Donnell et al. 2013).   
 
Although  the  initiation of ULT  is  recommended  in  those with  recurrent  attacks of  gout,  tophi, 




Fitzgerald  et  al.  2012).   ULT  is  usually  initiated  once  the  acute  attack  subsides  (usually  2  to  4 
weeks) to reduce the risk of drug induced acute gout (Roddy, Mallen et al. 2013).  Treatment with 





physician  and  patient  related  factors  (Doherty,  Jansen  et  al.  2012).    Although  health  care 
professionals  feel  that  they  have  adequate  knowledge  to manage  gout  (Harrold, Mazor  et  al. 



















































































































































































































































































































































































































































































































































































































































































































n = 18 
EMBASE  
n = 242 
MEDLINE  
n = 260 
PsycINFO  
n = 241 
Combined 
n = 761 
Duplicates 
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Title/abstract 
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Not gout n = 315 
Not HRQOL n = 84 
Not English n = 8 
No full text n = 21 
No empirical data n = 22 
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review 
n = 24 
Included  
n = 22 
Excluded 
Not gout n = 1 
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NR  2007  UK  Two GP practices  Cross‐sectional  13,684  WHOQOL‐BREF 
Dalbeth, Taylor 
et al. 2009 
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GIS  ++  0  +  ‐  +  ++  + 
GAQ  ++  0  +  0  ++  0  ‐ 
HAQ‐DI  +  ‐  ++  ++  ++  ++  + 
HAQ II  +  ‐  ++  ++  ++  0  0 
SF‐36  0  ‐  +  0  ++  +  + 
MOS 20  +  0  0  ‐  +  ‐  + 
PF‐10  ‐  0  +  ++  ++  0  0 



















































































































































































































































































































































































































































































































Conceptual domain  Operational definition  Empirical measure  Number of 
items  




Age at diagnosis  Age in years  Numerical free text box  1 














Illness perception  Modified IPQ (Moss‐Morris, Weinman et al. 2002)  5‐item Likert scale  4 














































































Conceptual domain  Operational definition  Empirical measure  Number of 
items  
Education  Higher education  Yes/No  1 









































































































































































































































































































































































































































































































































































































































































































































































































































  All mailed, n (%)  Responders, n (%)  Non‐responders and refusals, n (%) 
n  18057  1184  612 
Male  1471 (81.5)  990  (83.6)  476 (77.8) 
Female  334 (18.5)  194 (16.4)  136 (22.2) 
Age (years)  <40  80 (4.4)  26 (2.2)  53 (8.7) 
  40‐49  228 (12.6)  116 (9.8)  111 (18.1) 
  50‐59  348 (19.3)  210 (17.7)  137 (22.4) 
  60‐69  480 (26.6)  343 (29.0)  136 (22.2) 
  70‐79  448 (24.8)  339 (28.6)  107 (17.5) 
  ≥ 80  221 (12.2)  150 (12.7)  68 (11.1) 
Age (years), 
Males 
<40  78 (5.3)  25 (2.5)  52 (10.9) 
  40‐49  216 (14.7)  113 (11.4)  103 (21.6) 
  50‐59  301 (20.5)  187 (18.9)  113 (23.7) 
  60‐69  401 (27.3)  293 (29.6)  108 (22.7) 
  70‐79  340 (23.1)  273 (27.6)  65 (13.7) 
  ≥ 80  135 (9.2)  99 (10.0)  35 (7.4) 
Age (years) 
Females 
<40  2 (0.6)  1 (0.5)  1 (0.7) 
  40‐49  12 (3.6)  3 (1.5)  8 (5.9) 
  50‐59  47 (14.1)  23 (11.9)  24 (17.6) 






  All mailed, n (%)  Responders, n (%)  Non‐responders and refusals, n (%) 
  70‐79  108 (32.3)  66 (34.0)  42 (30.9) 
  ≥ 80  86 (25.7)  51 (26.3)  33 (24.3) 
Neighbourhood 
deprivation8 



































































































































































































































































































































































































































































































































































































































































































































































































  Mean (SD)            
PF‐1016  75.86 (26.12)             
HAQ‐DI17  0.51 (0.71)             
GIS18 CO  48.65 (28.33)            
GIS MSE  40.45 (26.33)            
GIS UTN  33.46 (20.57)            
GIS WBDA  45.19 (26.41)            
























































History of O/P attacks  On allopurinol  Tophi  SUA ≤ 360 












































































History of O/P attacks  On allopurinol  Tophi  SUA ≤ 360 































































































History of O/P attacks  On allopurinol  Tophi  SUA ≤ 360 












































































































































































































0 to 9 10 to 19 20 to 29 30 to 39 ≥ 40
HAQ‐DIPF 10 and GIS
Disease Duration (years)






































































































































































































































































































HRQOL scores  Diabetes  Hypertension  Hyperlipidaemia  Kidney failure  Renal calculi 






































































































HRQOL scores  Diabetes  Hypertension  Hyperlipidaemia  Kidney failure  Renal calculi 





























































































  Stroke  TIA  MI  Angina  Body pain 





























































































































  Stroke  TIA  MI  Angina  Body pain 









































































































































































































































































































































































































































































































































































































































































































































































































































less than 40 40 to 59 60 to 79 ≥ 80
HAQ‐DIPF10 and GIS
Age (years)





















































































































































































































































































(68.17, 74.02)  (0.57, 0.73)  (49.44, 55.06)  (40.50, 45.73)  (31.60, 35.81)  (47.03, 52.24)  (41.00, 45.85) 
P value for 
ANOVA 
















































































































































































































































































































































































































  PF‐10  HAQ‐DI  GIS CO  MSE  UTN  WBDA  CDA 
Mean  75.29  0.46  46.99  39.79  32.59  45.54  39.32 
Median  90  0  50  37.5  33.33  45.45  37.5 

























































































































  Unadjusted β (95% CI)  N  Adjusted β26 (95% CI)  n 
Gout characteristics         
Frequency of attack  ‐3.50 (‐4.46, ‐2.53)  910  ‐1.37 (‐2.31, ‐0.44)  551 
Current gout attack  13.78 (8.58, 18.97)  921  ‐0.92 (‐5.52, 3.67)  551 
Oligo‐polyarticular attacks  9.13 (5.71, 12.56)  919  2.26 (‐0.67, 5.19)  551 
Treatment with allopurinol  1.67 (‐1.75, 5.10)  910  2.00 (‐0.83, 4.83)  551 
Dose of allopurinol  8.41 (4.29, 12.53)  472  2.53 (‐0.67, 5.72)  327 
Tophi  ‐7.94 (‐19.26, 3.38)  856  ‐5.14 (‐14.02, 3.75)  581 
Disease duration  0.71 (‐0.72, 2.14)  955  1.09 (‐0.12, 2.30)  551 
Serum uric acid  1.41 (‐4.63, 7.45)  379  ‐0.86 (‐5.75, 4.04)  256 
Co‐morbid characteristics      Adjusted β27 (95% CI)   
Diabetes  ‐11.35 (‐15.67, ‐7.03)  958  ‐2.66 (‐6.29, 0.97)  603 
 Stroke  ‐17.33 (‐26.79, ‐7.88)  958  ‐7.35 (‐15.16, 0.46) 
Hypertension  ‐8.19 (‐11.56, ‐4.82)  958  0.65 (‐2.35, 3.65) 
TIA  ‐0.18 (‐7.62, 7.25)  958  3.08 (‐3.04, 9.20) 
Hyperlipidaemia  ‐2.96 (‐6.30, 0.39)  958  1.49 (‐1.36, 4.35) 
Kidney failure  ‐18.29 (‐26.01, ‐10.58)  958  ‐3.98 (‐10.27, 2.30) 
MI  ‐11.82 (‐17.28, ‐6.36)  958  ‐2.11 (‐6.81, 2.58) 
Kidney stones  1.49 (‐5.07, 8.05)  958  6.36 (1.10, 11.62)28 
Angina  ‐16.59 (‐21.50, ‐11.68)  958  ‐6.17 (‐10.46, ‐1.87) 









  Unadjusted β (95% CI)  N  Adjusted β26 (95% CI)  n 
Anxiety  ‐12.61 (‐14.68, ‐10.55)  886  ‐0.40 (‐2.96, 2.15) 
Depression  ‐13.98 (‐15.58, ‐12.38)  840  ‐10.74 (‐12.89, ‐8.59) 
Socio‐demographic characteristics      Adjusted β29 (95% CI)   
Age  ‐11.61 (‐13.96, ‐9.26)  958  ‐11.10 (‐13.37, ‐8.83)  603 
Gender  ‐21.30 (‐25.57, ‐17.03)  958  ‐11.17 (‐15.10,  ‐7.24) 
Neighbourhood deprivation  3.24 (2.08, 4.40)  958  1.08 (0.13, 2.04)30 
Ethnicity  0.45 (‐7.03, 7.93)  958  0.54 (‐5.53, 6.62) 
BMI  ‐3.28 (‐5.56, ‐1.01)  900  ‐1.48 (‐3.29, 0.34) 
Further education  ‐10.10 (‐14.13, ‐6.07)  914  ‐2.64 (‐5.88, 0.60) 
Alcohol frequency  ‐5.34 (‐6.31, ‐4.37)  944  ‐1.96 (‐2.84, ‐1.08) 








































  Unadjusted β (95% CI)  Residual n  Adjusted β31 (95% CI)  Residual n 
Gout characteristics         
Frequency of attack  0.09 (0.06, 0.11)  1087  0.02 (0.00, 0.05)  667 
Current gout attack  ‐0.40 (‐0.53, ‐0.27)  1099  ‐0.04 (‐0.16, 0.08)  667 
Oligo‐polyarticular attacks  ‐0.29 (‐0.37, ‐0.20)  1096  ‐0.09 (‐0.16. ‐0.01)  667 
Treatment with allopurinol  ‐0.12 (‐0.20, ‐0.03)  1085  ‐0.09 (‐0.16, ‐0.01)  667 
Dose of allopurinol  ‐0.19 (‐0.30, ‐0.08)  583  ‐0.03 (‐0.13, 0.07)  401 
Tophi  0.30 (0.02, 0.59)  1028  0.19 (‐0.05, 0.43)  700 
Disease duration  0.02 (‐0.02, 0.05)  1139  0.00 (‐0.03, 0.03)  667 
Serum uric acid  ‐0.04 (‐.20, 0.11)  447  0.04 (‐0.09, 0.18)  305 
Co‐morbid characteristics      Adjusted β32 (95% CI)   
Diabetes  0.35 (0.24, 0.46)  1142  0.10 (0.00, 0.20)  725 
Stroke  0.53 (0.29, 0.76)  1142  0.26 (0.06, 0.47) 
Hypertension  0.21 (0.13, 0.30)  1142  ‐0.04 (‐0.12, 0.04) 
TIA  ‐0.03 (‐0.22, 0.16)  1142  ‐0.15 (‐0.32, 0.01) 
Hyperlipidaemia  0.09 (0.01, 0.17)  1142  ‐0.02 (‐0.09, 0.06) 
Kidney failure  0.56 (0.37, 0.75)  1142  0.20 (0.03, 0.36) 
MI  0.30 (0.17, 0.44)  1142  0.05 (‐0.07, 0.18) 
Kidney stones  0.15 (‐0.02, 0.31)  1142  0.02 (‐0.12, 0.16) 
Angina  0.42 (0.29, 0.54)  1142  0.11 (0.00, 0.23) 
Body pain  ‐0.45 (‐0.54, 0.36)  938  ‐0.20 (‐0.28, ‐0.12) 







  Unadjusted β (95% CI)  Residual n  Adjusted β31 (95% CI)  Residual n 
Depression  0.38 (0.34, 0.42)  1016  0.30 (0.24, 0.36) 
Socio‐demographic characteristics      Adjusted β33 (95% CI)   
Age  0.28 (0.22, 0.34)  1142  0.27 (0.21, 0.33)  725 
Gender  0.54 (0.43, 0.64)  1142  0.28 (0.18, 0.39) 
Neighbourhood deprivation  ‐0.08 (‐0.11, ‐0.05)  1142  ‐0.02 (‐0.05, 0.00) 
Ethnicity  0.04 (‐0.15, 0.22)  1142  0.00 (‐0.16, 0.16) 
BMI  0.12 (0.06, 0.17)  1084  0.06 (0.02, 0.11)34 
Further education  0.21 (0.10, 0.31)  1085  0.02 (‐0.07, 0.11) 
Alcohol frequency  0.15 (0.13, 0.17)  1130  0.06 (0.04, 0.08) 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































430  F  76  GP  5  1 
452  M  75  K  5  2 
686  M  73  GP  2  2 
84  M  55  K  3  1 
441  M  67  K  1  2 
476  M  68  K  3  1 
478  M  85  K  3  2 
501  M  77  K  2  1 
562  M  72  GP  2  1 
387  M  81  K  3  1 
445  M  68  K  2  1 
237  M  64  K  2  2 
233  M  64  K  2  1 
407  M  78  K  3  1 
456  M  60  K  4  2 
463  M  63  K  3  1 
701  M  75  K  5  2 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Health-related quality of life in gout: a systematic
review
Priyanka Chandratre1, Edward Roddy1, Lorna Clarson1, Jane Richardson1,
Samantha L. Hider1 and Christian D. Mallen1
Abstract
Objectives. To identify the instruments that have been used to measure health-related quality of life
(HRQOL) in gout and assess their clinimetric properties, determine the distribution of HRQOL in gout
and identify factors associated with poor HRQOL.
Methods. Medline, CINAHL, EMBASE and PsycINFO were searched from inception to October 2012.
Search terms pertained to gout, health or functional status, clinimetric properties and HRQOL. Study data
extraction and quality assessment were performed by two independent reviewers.
Results. From 474 identified studies, 22 met the inclusion criteria. Health Assessment Questionnaire
Disability Index (HAQ-DI) and Short Form 36 (SF-36) were most frequently used and highest rated due
to robust construct and concurrent validity, despite high floor and ceiling effects. The Gout Impact Scale
had good content validity. Gout had a greater impact on physical HRQOL compared to other domains.
Both gout-specific features (attack frequency and intensity, intercritical pain and number of joints involved)
and comorbid disease were associated with poor HRQOL. Evidence for objective features such as tophi
and serum uric acid was less robust. Limitations of existing studies include cross-sectional design,
recruitment from specialist clinic settings and frequent use of generic instruments.
Conclusion. Most studies have used the generic HAQ-DI and SF-36. Gout-specific characteristics
and comorbidities contribute to poor HRQOL. There is a need for a cohort study in primary care
(where most patients with gout are treated) to determine which factors predict changes in HRQOL over
time. This will enable those at risk of deterioration to be identified and better targeted for treatment.
Key words: gout, health-related quality of life, clinimetrics.
Introduction
Gout is the most prevalent inflammatory arthritis, affecting
1.4% of adults in Europe [1]. Health-related quality of life
(HRQOL) may be adversely influenced by the excruciating
pain, chronic arthropathy, associated co-morbidities
(renal and cardiovascular disease, metabolic syndrome
and OA) and frequent suboptimal management in gout
[2]. The UK Department of Health and the Outcome
Measures in Rheumatology Clinical Trials (OMERACT)
group have identified HRQOL as a key component of
patient outcome assessment alongside the more trad-
itional markers such as survival rates, symptoms and
cost of resources [3, 4]. HRQOL can be measured using
generic instruments, which allow HRQOL to be compared
between different disease states, or by disease-specific
instruments, which account for the specific facets of
individual diseases [5]. Recent interest in HRQOL in gout
patients has resulted in the development of a disease-
specific measure, the Gout Assessment Questionnaire
1.0 [6], which was subsequently revised, resulting in the
Gout Assessment Questionnaire 2.0 and its subscale, the
Gout Impact Scale (GIS) [7]. The aims of this systematic
review were to (i) describe which instruments have
been used to measure HRQOL in gout in existing studies,
(ii) describe the clinimetric properties of these instru-
ments, (iii) describe the distribution of HRQOL in gout
and (iv) identify which factors associate with poor
HRQOL in gout.
1Arthritis Research UK Primary Care Centre, Keele University, Keele,
Staffordshire, UK
Correspondence to: Edward Roddy, Arthritis Research UK Primary
Care Centre, Keele University, Keele ST5 5BG, UK.
E-mail: e.roddy@keele.ac.uk
Submitted 3 December 2012; revised version accepted 25 June 2013.
! The Author 2013. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use,






























A systematic search was undertaken using the following
databases from inception to October 2012: Medline,
EMBASE, CINAHL, PsycINFO and Cochrane database
of systematic reviews. The search aimed to identify
studies of self-reported HRQOL in gout as well as those
evaluating the clinimetric (measurement) properties of
instruments used to assess HRQOL in gout patients.
Clinimetrics is defined as a methodological discipline
focused on measurement issues [8, 9]. The clinimetric
properties of an instrument describe the quality of its clin-
ical measurements, e.g. validity, reliability and responsive-
ness. Search terms included gout, health or functional
status and HRQOL. These domains were combined with
filters for measurement properties, such as elicitation
method (scale, measure and questionnaire) and measure
of scientific quality (psychometrics, validity, responsive-
ness, reliability) [10].
To increase the recall of the search results, all terms
were typed as synonyms and free text and mapped to a
thesaurus. Truncated terms and wildcards were used spe-
cific to each database.
Eligibility criteria
The following inclusion criteria were applied: (i) adults
aged >18 years with gout, (ii) assessment of HRQOL or
evaluation of the clinimetric properties of one or more in-
struments and (iii) publication in English. Both primary
care and secondary care studies were included. Publica-
tions without empirical data (such as commentaries, edi-
torials and reviews), randomized controlled trials deemed
to be non-representative of a typical population with gout
and articles not available as full text were excluded.
Study selection
Titles and abstracts of identified articles were independ-
ently reviewed against the criteria above by two reviewers
(PC, LC). Articles that could not be excluded based on title
and abstract screening alone were included for full-text
review, carried out independently by the same two re-
viewers. Further exclusions were made based on re-
application of the inclusion and exclusion criteria. The
references of all full-text papers were examined for rele-
vant studies. Disagreements at all stages were arbitrated
through consensus meetings.
Data extraction
The following data were extracted: study design (length
and method of recruitment, inclusion and exclusion cri-
teria, controls), participants (sample size, geographic lo-
cation, setting, mean age, gender, ethnicity, method of
gout diagnosis), study response rate or attrition, methods
of measurement (follow-up, statistical analysis), HRQOL
scores and factors associated with poor HRQOL. The
Consensus-based Standards for the Selection of Health
Measurement Instruments (COSMIN) checklist was used
to extract data on the clinimetric properties of question-
naires [11].
Methodological assessment
The quality of the following clinimetric properties of
HRQOL instruments was assessed against a modified
version of the quality criteria for measurement properties
by Terwee et al. [12]—validity (content, known group, floor
or ceiling effects, construct and concurrent), reliability (in-
ternal consistency and testretest) and responsiveness.
Qualitative studies were assessed against the criteria set
by the Critical Appraisal Skills Programme (CASP) [13].
Cohort studies were assessed against the standards set
by the Newcastle Ottawa Scale (NOS) for assessing the
quality of non-randomized studies [14]. Assessment of the
methodological quality of cross-sectional studies included
modified components such as the baseline associates of
HRQOL, response rate and a measure of association be-
tween poor HRQOL in gout compared with controls, in
addition to the NOS quality assessment scale.
Results
Study selection
A total of 761 potentially relevant articles were identified:
474 articles were included in title and abstract screening
after removal of duplicated papers. After full-text review of
the remaining 24 articles as well as 5 articles identified
from reference lists, 22 articles met the inclusion criteria.
Reasons for exclusion are described in Fig. 1. Included
studies are summarized in Table 1.
Study characteristics and methodological quality
Of the 22 included studies, 8 evaluated clinimetric proper-
ties of instruments used to measure HRQOL [4, 6, 7,
1519] and the remainder focused on self-reported
HRQOL or health care utilization [20, 2132]. One study
reported both the measurement properties as well as the
scores of HRQOL as measured by the Health Assessment
Questionnaire Disability Index (HAQ-DI) and Short Form
36 (SF-36) [33]. All studies were published in or after
2006. A total of 13 cross-sectional [4, 7, 18, 2024,
2630], 7 cohort [6, 1517, 19, 25, 33] and 2 qualitative
studies [31, 32] were identified. The median sample size of
the 20 quantitative studies was 134 (range 4970 334).
Only four studies [17, 18, 22, 33] used the diagnostic
gold standard of MSU crystal identification from joint or
tophus aspirate [34]. Other methods of gout diagnosis in
studies included hyperuricaemia (n= 3) [6, 18, 19], ACR
classification criteria [35] (n= 11) [4, 7, 15, 16, 23, 25, 26,
28, 29, 31, 35], self-reported gout (n= 4) [19, 21, 22, 30],
physician diagnosis (n= 2) [22, 24] and ICD-9 codes (n= 1)
[20]. The follow-up period in cohort studies ranged from
8 weeks [16, 19] to 2 years [17]. Five cross-sectional stu-
dies reported response rates of >60% [7, 18, 22, 24, 29].
Quality assessment of cohort and cross-sectional studies
is summarized in Table 2 (for qualitative studies, see sup-
plementary Table S1 available as supplementary data at
Rheumatology Online).
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Instruments used to measure HRQOL in gout
Twelve different instruments to measure HRQOL were
identified (five studies employed more than one instru-
ment) [16, 18, 23, 25, 33]. Most commonly used were
the HAQ-DI (n= 6) [4, 15, 18, 23, 27, 33], SF-36 (n= 5)
[17, 20, 22, 23, 33], GIS (n= 4) [7, 19, 24, 26] and Health
Assessment Questionnaire II (HAQ II, n= 2) [18, 25]. The
Gout Assessment Questionnaire 1.0 (GAQ 1.0) [6], Arthritis
Impact Measurement Scale (AIMS) [16], Medical
Outcomes Survey 20 (MOS 20) [16], Brief Illness
Perception Questionnaire (BIPQ) [25], SF-36 Physical
Function 10 (PF10) [18], Short Form 12 (SF-12v2) [30],
HAQ [28], EuroQOL 5D (EQ5D) [23], Short Form 6D
(SF-6D) [30] and World Health Organisation Quality of
Life (WHOQOL)-BREF [21] were each used once.
Clinimetric properties of instruments used to measure
HRQOL in gout
Values of the measurement properties of identified instru-
ments are available in Table 3. Supplementary Tables S2
and S3 (available at Rheumatology Online) present quality
ratings assigned to the measurement properties assessed
against the modified guidelines by Terwee et al. [12].
Content validity was only established for the gout-specific
GIS and GAQ 1.0, which received patient and health care
provider input during the development of the question-
naires [6, 7]. The generic SF-36 (except PF10 [18]) and
the HAQ-DI [4, 1517, 33] performed well in the known-
group analysis based on self-reported general health,
comorbidities and correlation with disease characteristics.
The HAQ-DI, HAQ II and SF-36 had significant floor
(HAQ-DI 20.5%) and ceiling (HAQ-DI 34%, HAQ II
25.8%, SF-36 18.4%) effects, indicating a weakness in
the ability to differentiate between participants at the ex-
treme ends of the scale (no disability and severe disabil-
ity), leading to limited content validity and responsiveness
to change [4, 17]. The GIS showed poor construct validity,
with low correlations between the subscales of GIS
(except unmet treatment need) and physician-rated sever-
ity (r= 0.020.34), although moderate correlations were
seen with patient-rated severity (r= 0.310.45) [7, 19].
Correlations of the SF-36 Mental Component Summary
(MCS) (r=0.17 to 0.43) with the GIS were generally
higher than those seen with the Physical Component
Summary (PCS) (r=0.10 to 0.20) (NB correlation coef-
ficients are negative, as higher scores indicate better
health status on the SF-36 but worse health status on
the GIS [5]). The GAQ 1.0 had better correlation with the
MOS health distress questionnaire (r= 0.030.46) than
the SF-36 (PCS, r= 0.020.34; MCS, r=0.01 to 0.23)
[6]. The HAQ-DI and HAQ II correlated with each other
(r= 0.87) as well as the SF-36 (HAQ-DI, r=0.41 to
0.67; HAQ II, r=0.35 to 0.72) [15, 18]. Most instru-
ments had good or excellent internal consistency
(Cronbach’s a= 0.41.0), except the GIS (weak correlation
between items of the gout medication side effects and
unmet treatment needs) [7]. Testretest reliability was
low for the AIMS [intraclass correlation coefficient
(ICC) = 0.110.70] and the MOS 20 (ICC = 0.270.65) [16]
but acceptable for the HAQ-DI (ICC = 0.680.84) [15].
Responsiveness to clinical change was elicited by the
Minimal Clinically Important Difference (MCID) of 58
points for the subscales of the GIS [19], SF-36 [17] and
GAQ 1.0 (in all subscales except well-being anchored to
pain frequency) [6] and a 20% change in scores of the
AIMS and MOS 20 [16]. Effect sizes (ESs) of the PCS
(SF-36) improved from small (0.3) in the treatment with
colchicine only to large (0.99) in the urate lowering treat-
ment (ULT) and colchicine group [17]. The magnitude of
the ES was lower for the GIS (0.2180.376 in the minimally
improved and 0.1290.682 in the markedly improved
groups) [19] and moderate (0.62) for the HAQ-DI [15].
The distribution of HRQOL in gout
No studies were identified that defined or used a cut-off
value for poor HRQOL in gout. Higher scores indicate
worse HRQOL in the GIS, GAQ 1.0, HAQ-DI, AIMS and
BIPQ and better HRQOL in the WHOQOL-BREF, SF-36
including PF10, MOS 20 and SF-12v2. Four studies iden-
tified instruments with scores lower than controls (SF-36
physical functioning, role physical, bodily pain, general
health, role emotional, PCS P< 0.001 [20]; WHOQOL-
BREF P= 0.003 [21]) and USA normative distribution
(SF-36 PCS P= 0.007 [22], P< 0.001 [30]), representative
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of poor HRQOL in gout. One cohort study of treatment-
failure gout showed lower scores in all SF-36 domains
(except mental health and MCS) compared with age-
and sex-matched US normative distributions (PCS and
MCS normative distributions have a mean of 50 and a
standard deviation of 10 for the US population) [33]. One
cohort [17] and two cross-sectional studies [21, 22] high-
lighted the greater impact of gout on physical HRQOL as
measured by the SF-36 [17] and WHOQOL-BREF
(P< 0.001) [21], with a lesser reduction seen in the MCS
compared with US norms (P< 0.001) [22]. However, the
impact on physical function was mild, as shown in two
studies using the HAQ-DI, with a baseline HAQ-DI of 1
for those with treatment-failure gout [33] and 0.43 in
chronic tophaceous gout [16]. (Consensus-based cut-off
for mild disability as measured by the HAQ-DI is a score
<1, moderate disability 12 and severe disability52 [36].)
Similarly the average HAQ score (surrogate for musculo-
skeletal disability) in another study was 0.17 [28]. Two
cross-sectional studies [27, 30] comparing the impact of
gout with that of other rheumatic diseases showed sub-
stantially lower levels of disability (mean HAQ-DI 0.54) in
patients with gout compared with those with RA (0.97) and
OA (1.00) [27]. Those with severe gout (three or more
flares in the previous year and confirmed tophi) had similar
health utility (SF-6D) scores as patients with average RA
or systemic lupus [36]. In two studies that utilized the
GIS, participants’ gout concern remained high despite
their reporting that they found treatment helpful [19, 24],
and in another cohort study using the generic BIPQ, the
impact of gout was most severe on perceptions of chron-
icity [25]. Gout severity was also associated with an
increased utilization of primary care clinics in a cross-
sectional study of health care resources utilization
(P= 0.005) [29].
Factors associated with poor HRQOL in gout
Two studies of physical functioning (measured by the
SF-36 and HAQ-DI) as a surrogate marker of HRQOL
and another study of health care utilization found that
associated comorbidities contribute to poorer HRQOL
(PCS, r=0.18 to 0.43, P< 0.01 [22]; HAQ-DI,
P< 0.03 [33]) and a greater number of primary care
visits (P= 0.006) [29]. In one study of US veterans, comor-
bidities were solely responsible for poor HRQOL, with no
difference in HRQOL between those with and without gout
after comorbidities had been adjusted for [20]. However,
in one cross-sectional study the association between gout
and poor physical HRQOL of the WHOQOL-BREF re-
mained significant after adjustment for medical (diabetes,
hypertension and chronic kidney disease) and musculo-
skeletal comorbidities (WHOQOL-BREF, P= 0.001 [21]).
Cross-sectional association of gout characteristics [pres-
ence of tophi (PCS, P< 0.01; MCS, P< 0.05), uncertainty
about the presence of tophi (PCS, P< 0.001; MCS,
P< 0.01) and four or more flares in the last 12 months
(PCS, P< 0.05; MCS, P< 0.05)] with poor HRQOL and
high activity impairment also remained significant even
after adjustment for comorbidities [30]. In one cohort
[25] and four cross-sectional studies [7, 22, 28, 30],
gout-specific features, including increasing frequency of
flares (P= 0.002 [22], P= 0.044 [25], r= 0.51 [7], P< 0.05
[30]), time with pain between attacks (P< 0.001 [22]), pain
during a typical attack (P= 0.023 [22]), number of joints
involved in a typical attack (P= 0.004 [22]) and presence
of tophi {relative risk (RR) = 4.3, 95% confidence interval
(CI) 1.2, 15.1 [28], P< 0.05 [30]} were reported to be asso-
ciated with worse HRQOL (measured by the GIS, SF-36,
SF-12v2, HAQ and BIPQ) even after adjustment for age,
gender, gout features and comorbidities. Increased fre-
quency of flares in the previous year (three or more)
(PCS, P< 0.05) and confirmed tophi (severe gout) (PCS,
P< 0.01; MCS, P< 0.01) led to worse HRQOL compared
with asymptomatic patients [30]. The presence of tophi
had a significant impact on activity impairment (P< 0.05
[30]) and led to an increased likelihood of consultation with
a rheumatologist {odds ratio (OR) = 7.92, 95% CI 2.81,
22.34, P< 0.0001 [29]} in two cross-sectional studies
[29, 30]. Other cross-sectional variables such as phys-
ician-rated severity (primary care OR = 1.46, 95% CI
1.02, 2.08, P= 0.037; rheumatologist OR = 1.52, 95% CI
1.08, 2.14, P= 0.018), time since last gout attack (primary
care OR = 0.65, 95% CI 0.55, 0.76, P< 0.0001; rheuma-
tologist OR = 0.78, 95% CI 0.67, 0.91, P= 0.001) and an
attack within the last 3 months (primary care OR = 3.48,
95% CI 1.84, 6.58, P< 0.0001; rheumatologist OR = 2.11,
95% CI 1.22, 3.65, P= 0.008) were also associated with
health care resources utilization [29]. While some studies
support the association of tophi (GIS, P= 0.029 [24]; PCS,
P< 0.01; MCS, P< 0.05 [30]) and serum uric acid (SUA)
(P= 0.002) [25] with poor HRQOL, others do not (tophi:
patient-severity rating, r= 0.174 [26]; SUA: WHOQOL-
BREF, P= 0.750 [21]; GIS, r< 0.29 [24]; patient-severity
rating, r= 0.06 [26]). There was a paucity of cross-sec-
tional evidence for positive effects of allopurinol on
HRQOL from a patient’s perspective (WHOQOL-BREF,
P= 0.618 [21]; HAQ, P= 0.79 [28]), whereas steroid and
non-steroidal anti-inflammatory drugs were associated
with greater musculoskeletal disability [28]. Although
tophi, comorbidities, polyarticular disease and radio-
graphic damage were associated with worse HRQOL
at baseline, after multivariate analysis, a reduction in
flares (P= 0.0010.06) and baseline SUA (P= 0.0010.04)
were predictors of improvement in HRQOL in one co-
hort study [17].
Discussion
Although none of the identified instruments to measure
HRQOL in gout in this review were satisfactory in all
domains of the assessed clinimetric properties, generic
instruments (HAQ-DI, SF-36) received the highest ratings.
Correlations with clinical characteristics, other instru-
ments and change in scores coupled with clinical change
strengthened their construct and concurrent validity as
well as responsiveness. The SF-36 and HAQ-DI have
been endorsed by the OMERACT group as validated
tools to measure HRQOL and functional disability in
gout [37, 38]. While the generic instruments allow
www.rheumatology.oxfordjournals.org 2037












comparison between the impact of different diseases,
their treatments and cost-effectiveness analyses, they
may lack the sensitivity to capture the true impact of
gout, especially in those with less severe disease [39].
The disease-specific GIS may focus on HRQOL domains
more relevant in gout (hence a better correlation with pa-
tient-reported factors) and be more responsive to small
changes in health status [40]. However, it may miss
any unexpected adverse outcomes and does not allow
comparison between disease states. Furthermore, the
OMERACT group has not yet unreservedly endorsed the
Gout Assessment Questionnaire 2.0 and its GIS subscale
as fully validated HRQOL measures in chronic gout [38].
A consistent finding of all the instruments reviewed is
that people with gout had lower physical HRQOL com-
pared with the normative distribution [20, 22] as well as
study controls [21], even after adjusting for comorbidities
[7, 22, 24]. This may be due to the strong emphasis on
physical functioning as a surrogate measure for HRQOL in
the generic instruments. The impact of SUA and tophi
were variable, with some studies reporting an adverse
effect on HRQOL [17, 24] but others showing no effect
[21, 26]. SUA may have an indirect relationship with
HRQOL in gout, as it is positively correlated with the fre-
quency of flares in the last 12 months as well development
of tophi [28, 30, 41]. Although allopurinol is not perceived
by patients to improve HRQOL [21, 28], its use in primary
care is often suboptimal [42] and it has been shown to
reduce the number of flares as well as tophi [43, 44].
Patients may be unaware of the rationale behind ULT,
with many discontinuing treatment at the onset of flares
when ULT is initiated [32].
The robustness of the findings of this review is sup-
ported by data extraction and quality assessment using
validated tools by two independent reviewers. Our search
strategy included a filter that is 9097% sensitive in
retrieving clinimetric articles [12], therefore it is unlikely
that we would have missed any such articles. Never-
theless, the findings of the review need to be interpreted
in the context of the limitations of the study design as well
as those of the literature identified. A limitation is that the
articles included in the review were restricted to English
(due to a lack of translation facilities) as well as not
searching for grey literature (presumed low yield). The
generalizability of the results may be limited by the
highly selective populations studied (treatment failure or
chronic tophaceous gout in the intercritical stage, mainly
Caucasian males), study settings (private or specialist
clinics) and variable response rates.
Existing studies of HRQOL in gout are limited by their
paucity of longitudinal data, recruitment from highly se-
lective secondary care populations and use of mostly gen-
eric instruments to measure HRQOL. Hence there is a
need for a primary carebased prospective cohort study
using both gout-specific and generic questionnaires to
determine how HRQOL changes over time in the clinical
setting, where most patients with gout are treated, identify
which factors (such as disease characteristics, treatment,
comorbidities including anxiety and depression) predict
changes in HRQOL and also identify those at risk of de-
terioration to better target their treatment.
Rheumatology key messages
. Existing studies of gout most commonly use
generic measures of HRQOL.
. Gout is associated with poorer physical HRQOL.
. Poor HRQOL in gout is associated with both dis-
ease-specific characteristics and comorbidity.
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http://www.biomedcentral.com/1471-2474/13/219STUDY PROTOCOL Open AccessProspective observational cohort study of Health
Related Quality of Life (HRQOL), chronic foot
problems and their determinants in gout: a
research protocol
Priyanka Chandratre1*, Christian Mallen1, Jane Richardson1, Keith Rome2, Joanne Bailey1, Rajvinder Gill1,
Samantha Hider1, Jane Mason1, Zoe Mayson1, Sara Muller1, Charlotte Purcell1, Jennifer Titley1, Simon Wathall1,
Irena Zwierska1 and Edward Roddy1Abstract
Background: Gout is the commonest inflammatory arthritis affecting around 1.4% of adults in Europe. It is
predominantly managed in primary care and classically affects the joints of the foot, particularly the first
metatarsophalangeal joint. Gout related factors (including disease characteristics and treatment) as well as
comorbid chronic disease are associated with poor Health Related Quality of Life (HRQOL) yet to date there is
limited evidence concerning gout in a community setting. Existing epidemiological studies are limited by their
cross-sectional design, selection of secondary care patients with atypical disease and the use of generic tools to
measure HRQOL. This 3 year primary care-based prospective observational cohort study will describe the spectrum
of HRQOL in community dwelling patients with gout, associated factors, predictors of poor outcome, and
prevalence and incidence of foot problems in gout patients.
Methods: Adults aged ≥ 18 years diagnosed with gout or prescribed colchicine or allopurinol in the preceding
2 years will be identified through Read codes and mailed a series of self-completion postal questionnaires over a
3-year period. Consenting participants will have their general practice medical records reviewed.
Discussion: This is the first prospective cohort study of HRQOL in patients with gout in primary care in the UK. The
combination of survey data and medical record review will allow an in-depth understanding of factors that are
associated with and lead to poor HRQOL and foot problems in gout. Identification of these factors will improve the
management of this prevalent, yet under-treated, condition in primary care.
Keywords: Gout, HRQOL, Foot, Patient experience, Prospective cohort, Primary careBackground
Gout is the most prevalent inflammatory arthropathy,
affecting around 1.4% of the adult population in the
UK [1]. It is caused by monosodium urate (MSU) crystal
deposition in and around joints once the physiological
saturation threshold in body tissues for uric acid is
exceeded. The most commonly affected joints are the
first metatarsophalangeal joint (1st MTPJ), mid foot and* Correspondence: p.chandratre@keele.ac.uk
1Arthritis Research UK Primary Care Centre, Keele University, Staffordshire ST5
5BG, UK
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© 2012 Chandratre et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumankle. The first acute attack affects the 1st MTPJ in 56-
78% of the patients with 90% having acute gout of the
great toe at some point in their disease course [2] yet
chronic foot problems are also common in people with
gout. Hallux valgus deformity and chronic pain in the
great toe are more common in people with gout than age
and gender-matched controls [3]. A small hospital-based
study has shown more frequent gait impairment and
foot-related functional problems in patients with gout
than in those without [4]. There is little evidence from a
primary care perspective about the potential long-term
consequences of gout for the foot.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.biomedcentral.com/1471-2474/13/219Gout also has an adverse impact on patients’ health
related quality of life (HRQOL) [5,6] and emotional,
social and physical functioning, resulting in significant
disability. Factors directly related to gout symptoms such
as frequency and severity of acute attacks as well as
those related to disease complications and adverse effects
of gout treatment, all potentially contribute to impaired
HRQOL. Cross-sectional epidemiological studies in pri-
mary care have shown that gout has an independent
association with impaired HRQOL, particularly affecting
the physical domain, after adjustments for co-morbidities
such as osteoarthritis, renal and cardiovascular disease
[6,7]. ‘Treatment failure’ gout within a hospital-based co-
hort has also been found to have a significant impact on
patient HRQOL and disability, especially in the realm of
physical functioning [5]. The same cohort study demon-
strated that the patients’ perception of disease severity cor-
related more closely with HRQOL than the physicians’
assessment of disease severity. Patients and healthcare
providers often have different perspectives of what consti-
tutes optimal management of gout [8]. Whilst physicians
regard pharmacological treatment of gout to be effective,
most patients discontinued treatment due to adverse or
no positive effects, treatment-induced flares and financial
constraints [8]. A recent qualitative study [9] on the im-
pact of gout highlighted the lack of understanding and
the stigma associated with this condition which often
leads to under-reporting of symptoms. This in turn can
lead to suboptimal treatment despite disease severity.
These findings are not surprising given that, until
recently, there has been little published work on the
implications of gout in terms of morbidity and mortality
as well as associated healthcare utilisation and costs [10].
The majority of gout is managed within the primary care
setting, yet most of the research to date has taken place
in secondary care which may deal with more complex
and atypical presentations including those who have
failed to respond to or not tolerated standard therapies.
Therefore the applicability of such data is questionable in
the wider community setting. Existing epidemiological
studies have had limitations such as small sample size,
cross-sectional design and the use of generic rather than
disease-specific instruments such as the Gout Impact
Scale (GIS) to measure HRQOL [11]. Little is known
about the changes in HRQOL in gout patients due to the
lack of longitudinal follow-up.
Hence there is a need for a prospective observational
cohort study in primary care which incorporates patient-
reported outcomes (PRO) to assess long-term outcome
and consequences of gout, focusing particularly on
HRQOL and foot problems. Improving understanding of
which factors predict outcome would help substantiate
indications for urate-lowering therapy (ULT) and identi-
fication of patients at which this should be targetedObjectives of the study
1. To describe the spectrum of HRQOL in patients
with gout and its distribution by demographic,
socio-economic and anthropometric characteristics.
2. To describe the prevalence, onset, persistence and
progression of chronic foot problems in gout over
3 years.
3. To examine:
a) Cross-sectional associations between poor
HRQOL and gout disease characteristics and
treatment, chronic foot problems, co-morbidities,
and psychosocial factors in gout.
b) Change in HRQOL in gout over 3 years and
determine which of the associated factors may
predict deterioration or recovery.Methods
Design
A primary care-based prospective cohort study with linked
medical record review. All phases of the study have been
approved by the North West-Liverpool East Research
Ethics Committee (Reference number 12/NW/0297).
Sampling frame
Inclusion criteria
 Aged >18 years.
 Registered with 30 general practices in the West
Midlands, UK.
 Read code consultation for gout or a prescription for
colchicine or allopurinol during the preceding two
years.
Exclusion criteria
 Under 18 years of age.
 Vulnerable groups – e.g. significant cognitive
impairment, severe enduring mental illness, active
malignancy or other terminal illness.
 Those who are unable to complete the
questionnaires in English.
Data collection time points
The different phases of the study are illustrated in
Figure 1.
Phase 1: baseline postal questionnaire survey
Patient identification Staff from the West Midlands
North Primary Care Research (WMN PCR) will conduct
a single electronic search of the primary care records in
participating practices to identify patients with Read
codes for a consultation for gout or a prescription for
All adults aged 18 years and over registered with30 
general practices in West Midlands
Losses to follow-up
Phase 3: Mailed 6-month Follow-up Survey
Losses to follow-up
Phase 4: Mailed 12-month Follow-up Survey
Phase 5: Mailed 24-month Follow-up Survey
Phase 6: Mailed 36-month Follow-up Survey
Losses to follow-up
Consent for further contact
Phase 2: Medical 
Record review
Phase 1: Mailed Baseline Survey Questionnaire
Respondents to Baseline Survey Questionnaire
Figure 1 Flowchart of study procedure.
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Read codes used by the Arthritis Research UK Primary
Care Centre (ARUKPCC) to define gout are listed in
Table 1. The WMN PCR team members will screen the
mailing lists (prior to mailing) for patient deaths and
departures from the practice to ensure that patients areTable 1 Read Codes used to identify consultations with




EGTON 227 Gout NOS
OX2740G Gout Acute/ox
1443 H/O: gout
EMISR4QG01 Gouty tophi + Gout NOS
2D52 O/E - auricle of ear - tophi
669 Gout monitoringnot inappropriately contacted. The lead general practi-
tioner (GP) at each practice will be invited to identify
potentially vulnerable patients to be excluded.Initiating patient contact All eligible patients will be
sent a study pack from their GP containing a letter of in-
vitation, participant information sheet (PIS), a pre-paid
return envelope and a baseline self-completion question-
naire which will also include a consent form asking for
consent for further contact and review of their medical
records. Potential participants will be provided with a
contact name and telephone number should they have
any queries about the study. Patients will be informed
that they are under no obligation to participate and that
if they decline their normal clinical care will not be
affected in any way. Participants will be asked to return
completed questionnaires, and upon receipt by the re-
search centre, the response will be recorded against a
unique patient number in a mailing database.
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two weeks, those who have not responded will be sent a
reminder postcard from their GP. After a further two
weeks, a reminder letter with repeat baseline question-
naire will be sent to those who have yet to respond
(4 weeks after the first questionnaire). Those who fail to
respond after all three baseline mailings will be assumed
not to have consented to the study and will not be con-
tacted again.
The questionnaire The questionnaire will be divided
into 7 main sections
a) Gout symptoms and treatment.
b) The impact of gout on daily life.
c) General health (including co-morbidities and
measures of physical function).
d)Measures of anxiety and depression.
e) Foot and other joint problems.
f ) Occupational characteristics.
g) Socio-economic and demographic characteristics.
Details of the conceptual domains, operational defini-
tions and empirical measures are provided in Table 2.
The completed baseline questionnaires will have the
responses securely stored in the study database.
Data entry, coding, cleaning and storage A specific
study database will be created to record responses to the
questions. Data entry will be performed by dedicated
trained members of the administrative team as the com-
pleted questionnaires are returned. Although they are
experienced in data entry, specific training will be pro-
vided for this study. The principal investigator (PI) and
study statistician will determine coding prior to data entry
into the database which will provide coding options. One
in ten random questionnaires will be checked by a mem-
ber of the study team for the purposes of quality assur-
ance. This information is kept by the research support
co-ordinator. Only relevant members of the research
team will have access to the database which is password
protected. Requests for access to the data stored in this
database must be made in writing, along with an analysis
plan, to the Chief Investigator (CI). Questionnaires and
consent sheets are securely stored in separate locations
to protect patient confidentiality.
Phase 2: Review of general practice medical records
All participants in Phase 1 who give permission for
their GP records to be accessed will have their com-
puterised medical records tagged by a member of the
WMN PCR team. The practices participating in this
study are fully computerised and undergo annual audits
completed by the WMN PCR team to assess the qualityand completeness of the data at the practices [23]. All
consultations for the 2 years prior to study entry and
then prospectively for the three-year study period will be
identified. The data obtained will include co-morbidities,
repeat consultations for gout, prescription patterns and
referral to secondary care. All patient identifiable data
(name, contact details) will be removed from the medical
records and the consultation data will be linked to the
survey data by unique survey identifier.Phase 3, 4, 5 and 6: Follow-up at 6, 12, 24 and 36 months
Follow-up surveys will be mailed at 6, 12, 24 and
36 months to all participants in phase 1 who consented
to further contact. The focus of follow-up will be clinical
(pain/disability severity) change and the possible deter-
minants of this. The questionnaire will include repeated
measures of general health (including generic measures
of physical function), psychosocial factors, co-morbidity
and gout symptoms. Non-responders to the questionnaire
will be sent a reminder postcard after two weeks. Those
who do not respond to the reminder postcard will be sent
a repeat questionnaire, PIS and a further covering letter
four weeks after the initial mailing. The WMN PCR team
members will screen the mailing lists (prior to mailing)
for patient deaths and departures from the practice to
ensure that patients are not inappropriately contacted.Sample size Disease specific HRQOL scores will be
recorded using the Gout Impact Scale at baseline, 6, 12,
24 and 36 months. In order to use the information
recorded at all five points, a sample size of 882 would
allow a smallest meaningful difference in HRQOL of
0.2 standard deviation units to be detected between two
groups (441 subjects per group) defined in terms of fre-
quency of gout attacks (<2 attacks, ≥2 attacks per year)
using a linear mixed model (significance 0.05, power
90%, autocorrelation 0.8) [24]. Allowing for 70% response
at baseline and 30% drop out over the follow-up period
would require 1800 people with gout to be contacted at
baseline.Statistical analysis
Baseline
Descriptive statistics will be used to assess response bias,
along with the characteristics of the baseline population.
Factors associated with levels of HRQOL at baseline
will be assessed using students’ t-tests chi-squared tests,
and logistic regression, as appropriate.Follow-up Descriptive statistics will be used to assess
attrition bias and to describe the onset, and persistence
of foot problems and their characteristics.
Table 2 Questionnaire items




Section A: About Gout
Gout frequency No. of attacks in the last 12 months/since
last contact
Numerical rating scale 0-≥ 5 1 All
Age at diagnosis Age in years Numerical free text box 1 BL
Acute attack of gout Acute episode at time of questionnaire Yes/No 1 All
Allopurinol Reported use of allopurinol Yes/No 1 All
Current daily dose of allopurinol Nine daily dose options:
50 mg-900 mg
1 All
Section B: How gout affects your life
Gout concern, wellbeing, productivity,
convenience and satisfaction
Gout Impact Scale [11] 5-item Likert scale 18 All
Illness perception Modified Illness perception
questionnaire [12]
5-item Likert scale 4 BL, 12 months,
36 months
Section C: General Health
Physical function SF36 Physical function sub-scale
(PF10) [13]
3-item Likert scale 10 All
Health Assessment Questionnaire
Disability Index [14]
4-item Likert scale 17 All
Co-morbidities Diabetes mellitus, Renal failure,





Section D: How you feel
Depression Patient health questionnaire
(PHQ 9) [15]
4 point Likert scale 16 BL, 12 months,
36 months
Anxiety Generalised anxiety disorder questionnaire
(GAD) [16]
Section E: Foot and other joint problems
Hallux valgus Self-completed line drawings [17] 5 line-drawings for each
foot depicting increasing
severity of hallux valgus
2 BL, 12 months,
36 months
Pain Pain in the hands, hips, knees
and feet in the last year
Yes/No 4 BL, 12 months,
36 months




1 BL, 12 months,
36 months
Foot pain Foot pain, aching, stiffness in last
month [20]
Frequency on 5-point Likert
scale
1 BL, 12 months,
36 months




1 BL, 12 months,
36 months
Foot function Manchester Foot Pain and Disability
Index [22]
Frequency on 3-point likert
scale
17 BL, 12 months,
36 months
Consultation for foot problems Consultation with GP, physiotherapy,
podiatry, in last 12 months/since
last contact
Yes/No 4 BL, 12 months,
36 months
Section F: Work
Occupational characteristics Current employment status 11-response options 1 BL, 12 months,
36 months
Work absence during last 6 months
due to joint/back problems
Yes/No 1 BL, 12 months,
36 months
Ability to do usual job 5-response options 1 BL, 12 months,
36 months
Section G: Demographic/socioeconomic characteristics
Date of birth Date of birth Date of birth 1 BL
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Table 2 Questionnaire items (Continued)
Gender Gender Male/Female 1 BL
Anthropometric characteristics Height Meters or feet/inches 1 All
Weight Kilogram or stones/pounds 1 All
Marital status Marital status 6-response options 1 BL
Living alone Living alone Yes/No 1 BL
Adequacy of income Adequacy of income 4-response options 1 BL
Education Higher education Yes/No 1 BL
Ethnicity Ethnicity 6-response options 1 BL
Life-style-characteristics Frequency of alcohol consumption 6-response options 1 BL
Weekly amount of beer/spirits/wine
consumed
Free-text 1 BL
Smoking status 3-response options 1 BL
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predicting poor HRQOL and chronic foot problems pro-
spectively over three years.
Imputation techniques will be used to account for
missing data and loss to follow up, as appropriate.
Discussion
HRQOL is an important yet under-researched outcome
measure in chronic gout. To our knowledge this is the
first prospective observational cohort of gout patients in
primary care in the UK which uses generic as well as
gout-specific questionnaires to assess HRQOL. Through
follow-up surveys and medical record review, the study
investigates the occurrence and frequency of poor
HRQOL, factors associated with it at baseline and pre-
dictors of poor outcome at follow-up. A limitation of the
study is the identification of patients based on a clinical
diagnosis of gout (the gold standard of urate crystal
identification in synovial aspirate [25] is not mandatory
for inclusion into the study). However, a clinical diagnosis
based on the rapid onset of pain, erythema and swelling
affecting the 1st MTPJ in the context of hyperuricaemia
is supported by the European League Against Rheuma-
tism (EULAR) recommendations for the diagnosis of
gout [25]. Potential participants will be identified either
by a gout-coded primary care consultation or a prescrip-
tion for allopurinol or colchicine in the study period.
Other urate lowering therapies such as febuxostat and
uricosuric drugs will not be included in this search
strategy as both are infrequently used in UK primary care.
Patients taking either drug will be identified by regular
consultations. This study ultimately aims to improve the
management of gout in primary care through identifying
and considering factors associated with and predictive of
poor outcome in a patient-centred treatment plan.
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INSTRUCTIONS FOR THIS QUESTIONNAIRE 
Please answer all the questions. 
The questions can be answered by putting a cross in a box like this:  
 
or circling a number like this: 
3 4 5 6 
 
Please write in BLOCK CAPITALS where appropriate.  Please complete the con-
sent form on page 22 if you agree to take part in this study, then complete the 
questionnaire. 
 
When you have finished please check that you have answered all of the questions 
and then return the questionnaire in the envelope enclosed. You do not need a 
stamp. Please return the questionnaire in the next two weeks. 
 




Whether you take part in this research or not, your right to use health services at your 
practice or elsewhere will not be affected. 
 
Details about this project are available in the information sheet enclosed. If you would 
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SECTION A: ABOUT GOUT 
 
1. How many attacks of gout have you had in the last 12 months?  




 2..........  4................  
1................  3..........  5 or more..  
 
2. How old were you when you were first diagnosed with gout? 
 
Age  Years 
     
3. Are you having an attack of gout at the present?  
Yes  No  
 
4. Have you ever had gout in more than one joint at the same time?  
Yes  No  
 
5. Do you currently take a tablet called allopurinol for gout? 
 
If yes, please indicate the dose below 
50 mg...............  600 mg.............  
100 mg.............  700 mg.............  
200 mg.............  800 mg.............  
300 mg.............  900 mg.............  
400 mg.............  Don’t know.......  




Yes  No  
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SECTION B: HOW GOUT AFFECTS YOUR LIFE 
1. Please indicate how much you agree or disagree with the statements below 




Disagree Uncertain Agree Strongly 
agree 
a. I am worried that I will 
have a gout attack within 
the next year 
     
b. I am afraid that my gout 
will get worse over time 
     
c. I worry that I will not be 
able to continue to enjoy 
my leisure activities as a 
result of my gout 
 
     
d. I feel anxious that my 
gout will interfere with 
my future activities 
     
e. I am bothered by the 
side effects from my 
gout medications 
     
f. I am mad or angry when 
I experience a gout  
attack 
     
g. It is difficult to plan 
ahead for events or  
activities because I may 
have a gout attack 
     
h. I feel depressed when I 
get a gout attack 
     
i. My current medications 
are effective at treating a 
gout attack if I get one 
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Disagree Uncertain Agree Strongly 
agree 
j. I miss planned or  
important activities when 
I have a gout attack 
     
k. I worry about the long 
term effects of my gout 
medications 
 
     
l. My current medications 
do not work well to  
prevent gout attacks 
from happening 
     
m. I have control over my 
gout 
 
     
2. During your last gout attack, how much of the time did you experience the  
following?  
(Please put a cross in one box only for each statement).  
 
 













a. Miss work because of gout 
symptoms? 
     
b. Have difficulty working because 
of gout symptoms? 
     
c. Have difficulty with recreational 
or social activities because of 
your gout symptoms?  
 
     
d. Have difficulty with self care 
such as bathing, feeding ,  
dressing yourself because of 
gout symptoms? 
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3. During your last gout attack, how much did your symptoms interfere with the 
following things?  
(Please put a cross in one box only for each statement). 
 
4. Please indicate how much you agree or disagree with the statements below 
(Please put a cross in one box only for each statement).   
 Strongly 
disagree 
Disagree Uncertain Agree Strongly 
agree 
a. There is a lot I can 
do to control my 
gout  
     
b. What I will do will 
affect whether my 
gout gets better or 
worse 
     
c. Treatments are 
 effective in  
controlling gout 
     
d. Gout is a serious 
condition 
     




Moderately Quite    
a bit 
Extremely 
a. Your mood?      
b. Your ability to move 
about? 
     
c. Your sleep?      
d. Your normal work?  
(including both work 
outside the home and 
housework) 
     
e. Your recreational  
activities? 
     
f. Your enjoyment of life?      
g. Your ability to do what 
you want to do? 
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SECTION C: ABOUT YOUR GENERAL HEALTH 
We are interested in your general health. Please answer every question. Some 
questions may look similar to others but each one is different. Please take the time 
to read and answer each question carefully by placing a cross in the box of your 
choice. 
1. The following questions are about activities you might do during a typical day.  
Does your health now limit you in these activities?  If so, how much?  
(Please put a cross in one box on each line) 
 
 
 Yes, limited a 
lot 






a. Vigorous activities, such as 
running, lifting heavy objects, 
participating in strenuous 
sports 
   
b. Moderate activities, such as 
moving a table, pushing a   
vacuum cleaner, bowling or 
playing golf 
   
c. Lifting or carrying groceries    
d. Climbing several flights of 
stairs 
   
e. Climbing one flight of stairs    
f. Bending, kneeling or stooping    
g. Walking more than a mile    
h. Walking half a mile    
i. Walking one hundred yards    
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2. Please place a cross in the box which best describes your abilities over the past 
one week.  









a. Dress yourself  
including tying shoe-laces 
and doing buttons? 
    
b. Shampoo your hair?     
c. Stand up from a chair?     
d. Get in and out of bed?     
e. Cut your meat?     
f. Open a milk carton?     
g. Lift a full glass or cup to 
your mouth? 
    
h. Walk outdoors on flat 
ground? 




i. Climb up 5 steps?     
j. Wash and dry your entire 
body? 
    
 
 
k. Take a tub bath?     
l. Get on and off the toilet?     
m. Reach and get a 5 pound 
object such as a bag of 
sugar from above your 
head? 
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n. Open car doors?     
o. Open jars that have been 
previously opened? 
    
p. Bend down and pick up 
clothing from the floor? 
    
q. Turn taps on and off?     
r. Run errands and shop?     
s. Get in and out of a car?     
t. Do chores such as vacu-
uming or yard work? 
    
 
3. Do you use any aids or devices for any of the above activities?  
(Please put a cross in as many boxes as apply) 
a. Raised toilet 
seat.......................  
b. Devices used for dressing 
(button, hook, zipper pull, 
shoe horn etc.)..................  
c. Bathtub bar...........  d. Special or built-up chair....  





f. Built-up or special 
utensils............................. 
 




i. Long-handled  
appliances in bath-
room......................  
j. Walker..............................  





l. Crutches...........................  
m. Wheelchair............  n. Other (please specify)......  
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4. Do you receive any help from another person for; 
(Please put a cross in as many boxes as apply) 
 
a. Hygiene.....................  b. Dressing and  
Grooming.................  
c. Gripping and opening 
things.........................  
d. Arising......................  
e. Reach........................  f. Eating.......................  
g. Errands and chores...  h. Walking....................  
5. How much pain have you had in the past one week? On a scale of 0 to 10 
(where 0 represents “no pain” and 10 represents “pain as bad as can be”), please 
circle the number below. 
 
|_____|_____|_____|_____|_____|_____|_____|_____|_____|_____| 
0       1       2       3       4        5        6        7         8         9        10 
No pain         Pain as bad as can be 
6. Please rate how well you are doing on a scale of 0 to 10 (0 represents “very well” 
and 10 represents “very poor” health).   
Please circle the number below. 
 
|_____|_____|_____|_____|_____|_____|_____|_____|_____|_____| 
0       1       2       3       4        5        6        7         8         9        10 
Very well         Very poor health 
 
7. Have you ever been diagnosed as having or been treated for the following? 
(Please put a cross in as many boxes as apply) 
 
a. Diabetes......................................  b. Stroke..............  
c. High blood pressure....................  d. TIA or mini 
stroke............... 
 
e. High levels of cholesterol, fats or 
lipids in your blood.......................  
f. Kidney failure...  
g. Heart attack.................................  h. Kidney stones..  
i. Angina.........................................    
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SECTION D: ABOUT HOW YOU FEEL 
1. The next set of questions are about how you have felt over the last 2 weeks. 
Please read each item and put a cross in the box that comes closest to how you 
have been feeling in the past 2 weeks.  









a. Little interest in doing things     
b. Feeling down, depressed, or  
hopeless 
    
c. Trouble falling/staying asleep,  
sleeping too much 
    
d. Feeling tired or having little energy     
e. Poor appetite or overeating     
f. Feeling bad about yourself, or that 
you are a failure or have let  
yourself or your family down 
 
    
g. Trouble concentrating on things, 
such as reading the newspaper or 
watching TV 
 
    
h. Moving or speaking so slowly that 
other people could have noticed. Or 
the opposite - being so fidgety or 
restless that you have been 
moving around a lot more than   
usual.  
    
i. Thoughts that you would be better 
off dead or of hurting yourself in 
some way 
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2. If you have been bothered by any of the nine problems above, please answer the 
following: 
How difficult have these problems made it for you to do your work, take care of 
things at home, or get along with other people? 
(Please put a cross in one box only) 
Not difficult at all Somewhat difficult Very difficult Extremely difficult 
    
 
3. Over the last 2 weeks, how often have you been bothered by any of the follow-
ing problems?  
(Please put a cross in one box only for each statement) 










a. Feeling afraid that something awful 
may happen? 
 
    
b. Worrying too much about different 
things? 
 
    
c. Becoming easily annoyed or  
irritable? 
 
    
d. Feeling nervous, anxious or on 
edge? 
 
    
e. Not being able to stop or control 
worrying? 
 
    
f. Trouble relaxing?     
g. Being so restless that it is hard to sit 
still? 
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SECTION E: FOOT AND OTHER JOINT PROBLEMS 





















C D E A B 
We are interested in whether your big toes are straight or angled 
sideways because this might be related to your ability to move 
around. 
 
First, please look at your left big toe whilst standing without shoes 
and socks on.  Ignore the positioning and the gaps between your 
other toes and try to focus only on your big toe.  Select from the first 
set of pictures below labelled from A to E which one best shows the 
angle of your left big toe.  Please circle the letter of that picture. 
Now do the same for your right big toe joint using the set of pictures be-
low labelled from F to J.  Again please circle the letter of the picture that 
best shows the angle of your right big toe.  
A B C D E 
H I J F G 
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14 
Part 2: Pain and discomfort in the feet 











     
 
If ‘No days’ please continue with question 4 on page 16 
2. This question is about any recent pain you have had in your feet.  In the past 
month, have you had any ache or pain that has lasted for one day or longer in 

















Yes…...  → 
Please shade in the diagrams below any pain you have had in 
your feet in the last month that has lasted one day or longer 
No…….    
Right foot 
Sole / bottom Top 
Left foot 
Sole / bottom Top 
Ankles (back view) 
Left Right 357
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3. Below are some statements about problems related to pain in the feet. For each 
statement indicate if this has applied to you during the past month.   
(Please tick only one box for each statement).   
 
 




On most / every 
day(s) 
Because of pain in my feet:    
a. I avoid walking outside at all    
b. I avoid walking long distances    
c. I don’t walk in a normal way    
d. I walk slowly    
e. I have to stop and rest my feet    
f. I avoid hard or rough surfaces when 
possible 
   
g. I avoid standing for a long time    
h. I catch the bus or use the car more  
often 
   
i. I need help with housework/ shopping 
 
   
j. I still do everything but with more pain 
or discomfort 
   
k. I get irritable when my feet hurt    
l. I feel self conscious about my feet 
 
   
m. I get self conscious about the shoes I 
have to wear 
 
   
n. I have constant pain in my feet    
o. My feet are worse in the morning    
p. My feet are more painful in the even-
ing 
 
   
q. I get shooting pains in my feet    
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4. Have you consulted your GP (family doctor) in the past 12 months because of 
problems with your foot or feet?    
(Please put a cross in one box only)   
Yes  No  
 
5. Which of the following services have you used in the past 12 months because of 
problems with your foot or feet? For each service you have used please put a 
cross to show whether the NHS provided this, or if you had private treatment. If 
you have used both NHS and private services please cross both boxes. For any 
service you have not used please leave blank. 
 
 NHS Private 
a. Physiotherapy   
b. Podiatry   
c. Chiropody   
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Part 3 – Body Chart 
This question is about recent pain you may have had in any part of your body. By 
pain we also mean ache or discomfort or stiffness. Please do not include pain due 
to a feverish illness such as flu. If you are a woman please do not include pain re-
lated to your monthly period. 
In the past 4 weeks, have you had pain that has lasted for one day or longer in 
any part of your body? (Please put a cross in one box only) 
 
Yes…...  → 
Please shade in the diagram below any pain that has lasted for 
one day or longer in the past 4 weeks 
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SECTION F: HOW GOUT AFFECTS YOUR WORK 
 
THIS SECTION ASKS SOME GENERAL QUESTIONS ABOUT YOUR WORK 
1. Which of the following best describes your current situation?  
    (Please put a cross in one box only) 
Working full-time in a paid job.....................................................................  
Working part-time in a paid job...................................................................  
Employed, but currently off sick for 6 months or less.................................  
Looking after the home / children................................................................  
Not working, for more than 6 months due to joint problems.......................  
Not working, for more than 6 months for other reasons.............................  
Fully retired.................................................................................................  
Early retirement due to joint / back problems..............................................  
Early retirement for other reasons...............................................................  
Student........................................................................................................  
Other ..........................................................................................................  
 




2.  Have you taken time off work during the last 6 months because of gout? 
(Please put a cross in one box only) 
Yes  No  
 
361
The Gout Study - Baseline questionnaire booklet,  
Version 2.0, dated 08/05/12 
 
3. Are you currently 
(Please put a cross in one box only) 
a. Doing your usual job?  Please go to Section G on page 20.  
b. Working fewer hours?  
c. Doing lighter duties?  
d. On paid sick leave?  
e. On unpaid leave?  
 
 
If you have answered b) to e), please answer question 4.   
 
4.     If you are not doing your usual job, is this because of joint problems? 
 
 




The Gout Study - Baseline questionnaire booklet,  
Version 2.0, dated 08/05/12 
 
SECTION G: ABOUT YOURSELF 
 
THIS SECTION ASKS SOME GENERAL QUESTIONS ABOUT YOU  
1. What is your date of birth? 
/ /   
 (E.g. – if you were born on the 5th of June 1936, this would be entered as 05/06/36) 
2. Are you  
Male  Female  
 
3. What is your relationship status 
(Please place a cross in one box only) 
a. Married..............  b. Widowed......  
c. Co- habiting......  d. Divorced.......  
e. Separated.........  f. Single...........  
 
4. Did you go on from school to full-time education or university? 
 
Yes  If yes, what age did you finish full-time education?    years                 
No  
 
5. Is your ethnic origin?  (Please put a cross in one box only) 
 
a. White UK/European...........  b. Asian.................  
c. Afro Caribbean...................  d. African..............  
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6. What is your height?  
 Feet   inches  OR  cms  
 
7. What is your weight?  
 
 Stones  Ibs OR  kgs 
 
 
8. About how often do you drink alcohol?  
(Put a cross in one box only) 
 
a. Daily or almost daily............  
b. 3 to 4 times a week.............  
c. Once or twice a week.........  
d. 1 to 3 times a month...........  
e. Special occasions only......  
f. Never..................................   
 
9. In an average week how many  
    
 Number 
a. Small glasses (175 ml) of wine do you drink (there are roughly 6 
glasses per bottle)?........................................................................ 
 
 
b. Pints of beer do you drink (includes bitter, lager, stout and ale)?.. 
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SECTION H: CONSENT FORM 
Thank you for completing this questionnaire 
The nature of the questionnaire is not meant to be distressing in any way.  However, 
if the questionnaires lead to distress, unpleasant memories or thoughts, we would 
encourage you to contact your General Practitioner.  You may also wish to contact 
an independent mental health support group, which does not require referral from a 
doctor or a nurse.  All calls are free (call back also available), confidential and sup-
port is provided by trained staff.  The phone numbers of these support groups are 
listed below. 
Mental Health Helpline Staffordshire (Brighter Futures) 0808 800 2234  
Mental Health Helpline Shropshire 0800 195 1700  
Mental Health Helpline Wolverhampton 0800 387034 
 
Please ensure that you have read the enclosed information sheet that explains 
about the study and other similar questionnaires that will be sent to you in 6, 12, 24 
and 36 months time.  
 
Please read, complete and sign the consent form on the following page. 
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I confirm that I have read and understood the study information sheet and am willing 
to take part in the study.  I understand that I can withdraw from the study at any 
time, and that this will not affect the care I receive in any way.   
Please answer each statement by putting a cross in the box on each line 
 
 
Even if you would prefer us not to review your medical records or contact you again 
about the study, the answers you have given in this questionnaire will still be very 
important to us.  Please return your questionnaire in the FREEPOST (no stamp 
needed) envelope provided.  Thank you for your help with this research project.   
 Yes No 
I give my permission for my medical records to be reviewed by the re-
search team as part of the study……   
I am happy to be contacted again (this does not mean that you must 
take part in future - you are just agreeing to be contacted 
again)……………….………………………………………………   
I understand that my medical notes and data collected during the study 
may be looked at by individuals from regulatory authorities or from the 
NHS Trust, where it is relevant to my taking part in this research. I give 




















Postcode: ......................................................................................................................  
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GP Practice Name  
GP Practice Address 







Date         Study ID 
 
 
Dear (insert name), 
 
The doctors in this practice are working with researchers in the Arthritis Research UK Primary Care 
Centre, at Keele University. We are writing to you to see if you would be willing to help us with a 
research project. 
 
Researchers at Keele University are trying to find out about gout, to get a better understanding of 
this condition. Further details of the project are on the accompanying Participant Information Sheet. 
 
You have been sent this letter because you have been to see your GP with gout or have taken 
medications for gout during the last two years. We hope that you will be able to spare a short 
amount of time to complete the enclosed questionnaire. It should take you no more than 30 minutes 
to fill in.  
 
All of your answers will be dealt with in strict confidence. We can also assure you that whether 
or not you answer the questionnaire will not in any way affect the care you receive from this practice 
or elsewhere. 
 
We would be very grateful if you would return the questionnaire in the envelope provided in the next 
two weeks. You do not need a stamp. A short while after this date, we will send a reminder to 
people whose questionnaire we have not received. If you would like to know more about this study, 
please contact Priyanka Chandratre, at Keele University on 01782 734721.   
 
We will be asking you if you would be willing to help with this research study in the future, so we will 
also ask your permission to contact you again at the end of the questionnaire. In addition, we will 
ask your permission for review of your medical records. Full details of this research study are 
provided in the enclosed Participant Information Sheet.   
 






Name of GP(s)  
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PATIENT INFORMATION SHEET 
REC Reference Number 12/NW/0297 
Version 2.0, dated 08/05/12 
 
The Gout Study 
 
You are being invited to take part in a research study. Before you decide 
whether to take part, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information carefully. 
 
What is the purpose of the study? 
Your GP practice, together with Keele University, is carrying out a research 
study on gout.  Gout is the most common cause of inflamed joints in adults 
and can recur from time to time. Despite this, little is known about the way 
gout can affect peoples’ quality of life and how to identify and treat those who 
may be at risk of having a worse outcome than others. We are trying to find 
out more about how gout affects people in the community and how it changes 
over the time.   
 
Why have I been invited? 
You were selected because you have been to see your GP with gout or you 
have taken medication for gout during the last two years.  
 
Do I have to take part? 
Whether or not you take part in this research is up to you. If you do decide to 
take part, you are free to withdraw at any time without giving a reason. A 
decision to withdraw, or a decision not to take part, will not affect your right to 
access health services at your practice or elsewhere.   
 
How long will it take? 
Taking part in this study means that you are asked to complete the enclosed 
questionnaire.  We will also send you another similar questionnaire in 6, 12, 
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Future contact 
In the future, we may contact you again to ask you further questions about 
gout. We ask for your permission to contact you again on the last page of the 
questionnaire. If you agree to be contacted again, this does not mean that 
you must take part in future; you are only agreeing to be contacted again. 
 
What are the possible benefits of taking part? 
Although there are no immediate benefits to you as a patient, we hope that 
the insight we gain from this research will help patients in the future.  Your 
participation will help us to learn more about gout and how to best treat it in 
general practice.  
 
What are the possible risks of taking part? 
The nature of the questionnaire is not meant to be distressing in any way.  
However if the questionnaires lead to distress, unpleasant memories or 
thoughts, we would encourage you to contact your General Practitioner.  You 
may also wish to contact an independent mental health support group, which 
does not require referral from a doctor or a nurse.  All calls are free (call back 
also available), confidential and support is provided by trained staff.  The 
phone numbers of these support groups will also be provided at the end of 
each questionnaire.   
 
Mental Health Helpline Staffordshire (Brighter Futures) 0808 800 2234  
Mental Health Helpline Shropshire 0800 195 1700  
Mental Health Helpline Wolverhampton 0800 387034 
 
Will my taking part in this study be kept confidential? 
The answers you give in the questionnaire will be dealt with in strictest 
confidence. Each person who responds to the questionnaire will be given a 
code number, so the data from the study will not have any identifiable names 
and addresses, and cannot be traced back to you. On this basis, the data 
may be used in other research studies.  
 
How long will the answers to the study questionnaires be stored for? 
The questionnaires will be stored without identifiable names and addresses 
for twenty years in accordance with the Medical Research Council guidelines. 
Beyond this date records will be maintained if the study is still on-going. The 
questionnaires will be stored in a secure place.  Any identifiable personal 
information such as your name and address will however be destroyed at the 
end of the study period.  This will ensure that personal data will not be stored 
for longer than is necessary (Data Protection Act 1998).   
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Medical record review 
Another part of this study is to find out what other factors related to gout, such 
as your medications and other health problems may influence your quality of 
life. We can do this by reviewing your medical records, and we ask your 
permission to do this on the last page of the questionnaire. When reviewing 
medical records, your name will not be used so that you cannot be identified 
personally. All information will be held in strictest confidence. 
 
What will happen if I don’t want to carry on with this study? 
You can withdraw from this study at any stage by contacting Priyanka 
Chandratre, the Gout Study Co-ordinator on 01782 734721. Withdrawing 
means that we would no longer contact you directly, but we would still keep 
and use the information you have provided up to the point of your withdrawal. 
If you contact us to withdraw from the study, and you have consented to 
medical record review, we will check whether you also want us to stop 
reviewing your medical records. 
 
What will happen to the results of the research study? 
Because this is a large study, the results will not be available for about three 
years, and will then be published in medical journals and reports. The main 
findings from the study will be displayed on a poster in your practice. If you 
would like any other information after seeing this poster we will be happy to 
help. 
 
Who is funding and organising the research? 
The research is funded and organised by the Arthritis Research UK Primary 
Care Centre at Keele University.   
 
Who has reviewed the study? 
The Liverpool East Research Ethics Committee has reviewed this study 
(Research Ethics Committee Reference Number: 12/NW/0297). 
 
Contact for further information 
If you have any questions, or would like further information, about this study 
please contact  Priyanka Chandratre, the Gout Study Co-ordinator  on 
01782 734721.  If you have any questions or concerns about taking part in 
this research you can also contact the Patient Advice and Liaison Service 
(PALS). Your local PALS office phone number for NHS Stoke-on-Trent is 
0800 783 2865, Wolverhampton PCT is 01902 445378, NHS Telford and 
Wrekin is 01952 580478, NHS Shropshire county is 01952 580474, NHS 
South Staffordshire is 01543 465106 and for NHS North Staffordshire is 0800 
030 4563. 
 
Thank you for taking time to read this information leaflet. 
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The Gout Study – invitation letter sent regarding the focus group interview,  
version 1.0; dated 15/02/12 
 
 















 Study ID 
 
Dear (insert name), 
 
 
The Gout Study Interview 
 
 
Thank you for your recent response to our questionnaire about gout, in which you kindly 
agreed that we could contact you further. We hope that you will be interested in taking part 
in the interview stage of this study. Before you decide please take time to read the 
enclosed information sheet. This tells you why the interview is being carried out and what 
is involved if you agree to take part. 
 
Once you have decided whether or not you are interested in the study please return the 
enclosed reply slip in the stamped addressed envelope provided. Whether or not you take 
part in the interview will not affect your current or future health care in any way.  If you 
have any queries about the interview, please do not hesitate to contact Priyanka Chandratre, 
the Gout Study Co-ordinator on 01782 734721. 
 







Dr Edward Roddy 




The Gout Study Participant Information Sheet for gout interview (version 1.0, dated 15 02 12) 







The Gout Study – invitation letter sent regarding the focus group interview,  
version 1.0; dated 15/02/12 
 




Please tick one box and return this form in the stamped addressed envelope 
provided.  Thank you very much for your time and co-operation. 
 
 
Yes I would like to take part in the interview part of the gout study.  
 
 
No I do not wish to take part in the interview part of the study.  
 
 
Name  ____________________________________________________ 
 




Email  ____________________________________________________ 
 
 







The Gout Study – Two week reminder letter for focus group interviews,  
version 1.0; dated 15/02/12 
 
 












   Study ID 
 
 
Dear (insert name), 
 
 
The Gout Study focus group interview 
 
Reminder invitation to take part in the interview 
 
I write to remind you of the invitation to take part in the interview stage of the gout study. I 
appreciate that you may have been busy. If you have already contacted the Centre in the 
last few days I apologise for troubling you again and please ignore this letter. 
 
We are contacting you because you recently completed a questionnaire about gout.  We 
would like to talk to you about what it is like to have gout and what you would like your 
gout treatment to achieve or improve. The overall aim is to find out what aspects of gout 
and its treatment matter most to you.   
 
I have enclosed another copy of the information sheet explaining the study in more detail 
and how you can take part. Whether or not you take part in the interview will not affect 
your care now or in the future. Once you have decided whether or not you are interested in 
the study please return the enclosed reply slip in the stamped addressed envelope 
provided.  If you have any queries about the interview, please do not hesitate to contact 
Priyanka Chandratre, the Gout Study Co-ordinator on 01782 734721. 
 
Yours sincerely,  
 
 
Dr Edward Roddy 
Clinical Lecturer and Honorary Consultant Rheumatologist 
 
Enc: The gout study Participant Information Sheet for gout interview version 1.0 dated 15 02 
























































The Gout Study – Participant Information Sheet for Gout Interview,  
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PATIENT INFORMATION SHEET 
REC Reference Number 12/NW/0297 
Version 2.0, dated 08/05/12 
 
Your views about gout and its impact on your life  
– The Gout Study Focus Group Interview 
 
We are contacting you because you recently completed a questionnaire 
about gout.  You are now being invited to take part in a research interview 
about gout being conducted by the Arthritis Research UK Primary Care 
Centre, Keele University. Before you decide whether to take part it is 
important for you to understand why the research is being done and what it 
will involve.  
 
This leaflet explains what will happen if you agree to take part in the study. 
Please take time to read the following information carefully and discuss 
it with others if you wish. If there is anything that is not clear or if you would 
like more information then please contact  Priyanka Chandratre, the gout 
study co-ordinator on 01782 734721. 
 
Thank you for taking the time to read the information below. 
 
What is the purpose of the Interview? 
Previous research has shown that gout can affect people’s quality of life in 
several ways.  We would like to talk to you about what it is like to have gout 
and what you would like your gout treatment to achieve or improve. The 
overall aim is to find out what aspects of gout and its treatment matter most to 
you. We hope that the research will help us to understand better what having 
gout means to patients so that we can improve the way gout is managed in 
general practice.   
 
Where will the interview take place? 
The interview will take place either at the Arthritis Research UK Primary Care 
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Do I have to take part? 
You have been chosen because you agreed to further contact from the study 
team here at the Arthritis Research UK Primary Care Centre when you filled 
in a questionnaire earlier this year. This questionnaire was called “The Gout 
Study”.  
 
The next stage of the research involves interviewing people who have gout 
and we would like to invite you to take part in this. You are, of course, entirely 
free to decide whether or not to take part. If you do decide to take part you 
will be asked to sign a consent form at the time of the interview. If you decide 
to take part you are still free to withdraw at any time, and without giving a 
reason. Your decision as to whether or not to take part in the study, or any 
decision to withdraw from the study, will not affect the treatment you will 
receive, or any of your legal rights. 
 
What will happen to me if I take part? 
You will take part in a focus group interview. A group of people, all with gout, 
will take part in a discussion.  We will talk about what it is like to have gout, 
your views about the treatments you may have had for gout and what you 
would like the treatment to achieve or improve. The focus group interview is 
likely to last about one and a half hours. There will be approximately 5 people 
in the group.  We are interested in your views and experiences. There are no 
right or wrong answers. No preparation for the interview is necessary.  
 
We would like to tape-record the interview and will check that is convenient 
with you at the time. The interview will then be typed out.  Quotations from the 
interview may be used in reports of this study. Your identity will be hidden in 
any such report, and you will not be identified personally. The fact that you 
have taken part in the study will not be revealed to anyone outside the 
research team. If the interview contains comments or information that might 
identify a third party, or an institution (e.g., a GP, clinic or hospital), we will 
ensure that the person or institution cannot be identified in any account or 
published report of this study. You will be asked at the end of the interview if 
you are still happy to be included in the study. If you decide that you are no 
longer happy to do so, the information gathered in the interview will not be 
used and we will not contact you again.   
 
How long will information gathered from the interview be stored for?  
Both the tape (in a digital format) and the paper copy of the interview will be 
stored in a secure location for 20 years in keeping with guidance issued by 
the Medical Research Council and after this time they will be destroyed.  
Neither the audio tape nor the paper copy will bear any information that would 
identify you by name.  Both the tape and the paper copy of the interview will 
only be accessed by a small team of researchers working at the Arthritis 
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Research UK Primary Care Centre.  Any identifiable personal information 
such as your name and address will be destroyed at the end of the study 
period.  This will ensure that personal data will not be stored for longer than is 
necessary (Data Protection Act 1998).   
 
 
What are the possible benefits or risks of taking part? 
There are no risks relating to medical treatment in this study. Neither is there 
intended to be any medical benefit. There may be an indirect benefit to you 
and other patients from the insights we gain from this study, but we cannot be 
sure about this.  If an interview topic brings back unhappy memories or 
distressing thoughts that you do not wish to discuss, the topic will not be 
followed up again during the interview.  During the interview, you can choose 
not to answer questions, or to end the interview at any time, and for any 
reason.  You will also be offered the option of leaving the place where the 
interview is being held should you wish to do so.    
 
What will happen to the results of the interview? 
Because this interview is part of a large study, the results will not be available 
for about three years, and will then be published in medical journals and 
reports. The main findings from the study will be displayed on a poster in your 
practice. If you would like any other information after seeing this poster we 
will be happy to help. 
 
Who is organising and funding the research? 
This study is part of a programme of work into gout being conducted and 
funded by the Arthritis Research UK Primary Care Centre, at Keele 
University.  
  
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, 
called a Research Ethics Committee, to protect your safety, rights, well-being 
and dignity.  This study has been reviewed and given a favourable opinion by 
the Liverpool East Research Ethics Committee (reference number 
12/NW/0297).  
 
How can further information about the study be obtained? 
We will be glad to answer any questions that you may have about this study. 
For further information please contact  Priyanka Chandratre, the gout study 
co-ordinator at the Arthritis Research UK Primary Care Centre, at Keele 
University on 01782 734721.  
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Once  your  application  form has been  completed  and  signed off  as  appropriate, please 




If  you  have  concerns  regarding  the  disclosure  of  original  research  and  the  risk  of 
plagiarism during  the  review process please contact  the Chair of  the  Independent Peer 
Review Committee via Nicola Leighton 01782 733306. 
 


















































































































































































































































































































































































































































































b) Foot  related  disability  –  The  Manchester  Foot  Pain  and  Disability  Index 
(Manchester FPDI) 










































































































































































































































I  confirm  that  the  information 





















If  it  is  a  joint  project  between  the 
University  and  the  NHS  Trust,  or 
involves  both  the  University  and  the 




















I  confirm  that  I  have  read  this 
application  and  agree  that  if  approved 
it  will  be  accommodated  and 
administered  in  the  University  /  NHS 
Trust 
 
If  it  is  a  joint  project  between  the 
University  and  the  NHS  Trust,  or 
involves  both  the  University  and  the 


























Enterprise  Services,  Dorothy  Hodgkin  Building,  Keele  University,  ST5  5BG,  e‐mail 
n.leighton@keele.ac.uk.   
 







A pilot study  is one which acts as a precursor  to a  full study  in order  to determine  the 
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Introduction 
Gout is the most prevalent inflammatory arthropathy, affecting around 1.4% of the 
adult population in the UK (1). It is caused by monosodium urate (MSU) crystal 
deposition in and around joints once the physiological saturation threshold in body 
tissues for uric acid is exceeded.  The most commonly affected joints are the 1st 
metatarsophalangeal joint (MTPJ), mid foot and ankle.  The first acute attack affects 
the first MTPJ in 56-78% of the patients with 90% having acute gout of the great toe 
at some point in their disease course (2). Gout also associates with hallux valgus 
deformity as well as chronic pain in the great toe (2).  One further small hospital-
based study has shown more frequent gait impairment and foot-related functional 
problems in gout than controls (3).  With the exception of these two studies, there is 
little evidence from primary care about the potential long term consequences of gout 
as far as foot problems are concerned.  Gout is an important condition not only 
because it is an excruciatingly painful acute arthropathy but also because of its 
associations with chronic disease states such as metabolic syndrome, osteoarthritis 
and renal and cardio-vascular morbidity (4).  
In the face of such significant associated disorders, it is often difficult to attribute 
disability or diminished lifestyle to gout.  This may be an explanation for the 
relatively sparse literature available around health related quality of life (HRQoL) 
and disability in gout patients (5).  Most studies to date have had limitations such as 
small samples, cross sectional design and the use of generic instruments (which 
predate the disease specific Gout Impact Scale (GIS)) to measure HRQoL (6). Little 
is known about the changes in HRQoL in gout patients due to the lack of longitudinal 
follow up.  However, severe chronic gout, through its frequency and severity of 
episodes and recurrent pain, may have a great impact on patients HRQoL.  These 
symptoms, which may affect the patient’s emotional, social and physical functioning, 
result in significant disability.  Factors directly related to gout symptoms, as well as 
those related to disease complications and adverse effects of gout treatment, all 
potentially contribute to impaired HRQoL.  Cross-sectional epidemiological studies 
in primary care have also shown that gout has an independent association with 
impaired HRQoL, particularly affecting the physical domain, after adjustments for co-
morbidities such as osteoarthritis and vascular disease (7, 8). This finding is not 
unique - there are other studies emphasising the significant effect of ‘treatment 
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failure’ gout within a hospital-based gout cohort on patient HRQoL and disability, 
especially in the realm of physical functioning (5).  In a 52 week prospective 
observational study,  although co-morbidities contributed to impaired HRQoL, the 
scores were substantially lower than for the normative US adult male population, 
even for subjects who did not have any other illness (5). The same multi-centre 
prospective study demonstrated that the patients’ perception of disease severity 
correlated more closely with HRQoL than the physicians’ assessment of disease 
severity.  Patients and healthcare providers often have different priorities as far as 
the optimal management of gout is concerned (9).  A cross sectional qualitative 
study assessing the views of patients and physicians highlighted marked differences 
in what is important to each group.  Whilst the physicians regarded pharmacological 
treatment of gout to be effective, most patients discontinued treatment due to 
adverse or no positive effects, paradoxical flares and financial constraints.  Patients 
also expressed lack of understanding of gout, a disease physicians felt was easy to 
comprehend for the patients. Health care providers felt they had adequate training to 
educate patients about disease self management, an area patients wanted to know 
more about. A recent qualitative study (10) on the impact of gout highlighted the lack 
of understanding and the stigma associated with this condition which often leads to 
under reporting of symptoms. This in turn can lead to suboptimal treatment despite 
disease severity.   
These findings are not surprising given that, until recently, there has not been much 
published work on the implications of gout in terms of morbidity and mortality as well 
as associated healthcare utilisation and costs (11).  The majority of gout is dealt with 
within the primary care setting, yet most of the research to date has taken place in 
secondary care which may deal with more complex and atypical presentations 
including those who have failed to respond to or not tolerated standard therapies.  
Therefore the applicability of such data is questionable in the wider setting of the 
community.  There are several issues around the management of gout which need 
better understanding through robust research. At present it is estimated that only 
30% of patients take definitive treatment (e.g. allopurinol) for gout in primary care 
(12, 13). This is despite recommendations from international guideline groups which 
advocate the use of urate-lowering therapies (ULTs) such as allopurinol to lower uric 
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acid levels, shrink tophi and prevent acute attacks of gout (14, 15). There is no clear 
explanation for the discrepancy between the recommended and actual treatment of 
gout, although the potential for drug toxicity, interactions and polypharmacy 
associated with co-morbidity might reduce uptake of long-term treatment.   
International treatment recommendations suggest that patients experiencing two or 
more attacks in a 12-month period should be offered ULT but this recommendation 
is based upon expert consensus rather than empirical research evidence (15, 16). 
Improving understanding of which factors predict outcome would help substantiate 
indications for ULT and identification of patients at which this should be targeted. 
Hence there is a need for a well-designed and conducted prospective observational 
cohort study in primary care which incorporates patient reported outcomes (PRO) to 
assess long term outcome and consequences of gout, focusing particularly on 
HRQoL and foot problems.   
Objectives of the study 
The main objectives of the study are: 
1. To estimate the prevalence of poor HRQoL in patients with gout and its 
distribution by demographic, socio-economic and anthropometric characteristics 
(cohort study – baseline data). 
2. Describe the prevalence, onset, persistence and progression of chronic foot 
problems in gout over 3 years (cohort study – baseline and follow-up data). 
3. To examine: 
a) Cross-sectional associations between poor HRQoL and frequency of gout 
attacks, chronic foot problems, co-morbidities, gout treatment, and 
psychosocial factors in gout (cohort study – baseline data).  
b) Change in HRQoL in gout over 3 years and determine which of the 
associated factors may predict deterioration (cohort study – baseline and 
follow-up data).    
4. To explore patient experience of gout focusing on impact of gout and its 
treatment on HRQoL (cohort study – nested focus group interviews). 
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Methods /design 
Design 
Primary care-based prospective cohort study with follow-up focus group interviews.     
Sampling frame 
All adults (aged >18 years) registered with 30 general practices in the West 
Midlands who have had: 
 A consultation for gout in the preceding two years or,  
 Prescription for colchicine or allopurinol in the preceding two years.  
Patient eligibility 
Inclusion criteria 
 Registered with the participating general practice during the study  
 Read code consultation for gout or prescription for colchicine or allopurinol 
during the preceding two years 
 Provided written informed consent for participation in the study 
Exclusion criteria 
 Under 18 years of age 
 Vulnerable groups – e.g. significant cognitive impairment, severe enduring 
mental illness, active malignancy or other terminal illness.   
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Data collection time points 
 Phase 1: Baseline postal questionnaire  
 Phase 2: Review of general practice medical records 
 Phase 3: Focus group interviews (nested purposive sample) 
 Phase 4: Follow-up mailed survey at 6 months 
 Phase 5: Follow-up mailed survey at 12 months 
 Phase 6: Follow-up mailed survey at 24 months 
 Phase 7: Follow-up mailed survey at 36 months 
Phase 1: baseline postal questionnaire survey 
Patient identification 
All potentially eligible patients registered within the participating general practices 
will be identified through standard Read codes used for gout or prescription of 
colchicine or allopurinol.  The following Read codes are used by the Arthritis 
Research UK Primary Care Centre (ARUKPCC); 
Code Term 
C34 Gout 
N023 Gouty arthritis 
EGTON 227 Gout NOS 
OX2740G Gout Acute /ox 
1443 H/O: gout 
EMISR4QG01 Gouty tophi + Gout NOS 
2D52 O/E - auricle of ear - tophi 
669 Gout monitoring 
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Staff from the Keele Primary Care Research Network will conduct a one off 
electronic search of the primary care records in participating practices to identify 
patients with a consultation for gout or a prescription for colchicine or allopurinol 
within the last two years.  The names and contact details of the eligible patients will 
be stored in a password protected mailing database and held on the university’s 
firewall and password protected server.  No other information from the patients’ 
primary care records will be accessed or stored unless and until informed written 
consent to do so is obtained from the patient. The Primary Care Research Network 
team members will screen the mailing lists (prior to mailing) for patient deaths and 
departures from the practice to ensure that patients are not inappropriately 
contacted.  The lead general practitioner (GP) at each practice will be invited to 
identify potentially vulnerable patients to be excluded.   
Initiating patient contact 
All eligible patients will be sent a study pack from their general practitioner (on 
general practice headed notepaper).  This will contain a letter of invitation, 
participant information sheet (PIS), a pre-paid return envelope and a baseline self-
administered questionnaire which will also include a consent form asking for 
consent: 
a) For further contact by post 
b) For review of their medical records 
Potential participants will also be provided with a contact name and telephone 
number should they have any queries about the study.  Patients will be informed 
that they are under no obligation to participate and that if they decline their normal 
clinical care will not be affected in any way. On return of the questionnaire the 
response is recorded against a unique patient number – this will include completed 
questionnaires, contact details, request to be excluded from the study and non 
responders.  Participants returning their questionnaires with the consent sheet and 
those who wish to be excluded from the study (non-consenting responders) will be 
logged on the database so that no further reminders are sent to them.  The mailing 
database will determine future mailings.  By including the consent form with the 
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questionnaire we are hoping to avoid the wasteful exclusion of completed 
questionnaires but incomplete consent forms thereby preventing any adverse effects 
on data quality.  
The questionnaire 
The questionnaire will be divided into 7 main sections 
a) About gout symptoms and treatment 
b) The impact of gout on daily life 
c)  General health (including co-morbidities and measures of physical function) 
d) Measures of anxiety and depression in gout patients 
e) Foot and other joint problems 
f) Occupational characteristics 
g) Socio-economic and demographic characteristics 
Details of the conceptual domains, operational definitions and empirical measures 
are provided in Appendix 1. The completed baseline questionnaires will have the 
responses securely stored in the study database.  This database will be used in 
cross-sectional analyses where appropriate.   
Non-responders to mailed study pack 
As per the ARUKPCC questionnaire mailing Standard Operating Procedure, non-
responders are sent a reminder postcard at two weeks and a reminder letter with 
repeat baseline questionnaire two weeks later (4 weeks after the first questionnaire) 
(17).  This approach maximises response without placing significant burden on 
patients.  Those who fail to respond after all three baseline mailings will be assumed 
not to have consented to the study and will not be contacted again. 
Data entry, coding, cleaning and storage 
A specific study database will be created and tested using a set of dummy data first.  
Data entry will be performed by dedicated members of the administrative team as 
the completed questionnaires are returned. Although they are experienced in data 
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entry, specific training will be provided for this study.  The principal investigator (PI) 
and study statistician will determine coding prior to data entry into the database 
which will provide coding options.  Some standard codes (e.g. missing data (-9), not 
applicable (-88)) are used by the research centre and will also be utilised in this 
study.  One in ten random questionnaires will be checked by a member of the study 
team for the purposes of quality assurance. This information is kept by the research 
support co-ordinator and study statistician.  Only relevant members of the research 
team will have access to the database which is password protected.  Requests for 
access to the data stored in this database must be made in writing, along with an 
analysis plan, to the PI.  Questionnaires and consent sheets are securely stored in 
separate locations to protect the confidentiality of the patients.   
Phase 2: Review of general practice medical records 
All participants in Phase 1 who give permission for their GP records to be accessed 
will have their computerised medical records tagged by a member of the Primary 
Care Research Network.  All consultations for the 24-months prior to study entry and 
then prospectively for the three-year study period will be identified.  The practices 
participating in this study are fully computerised and undergo annual audits 
completed by the Primary Care Research Network to assess the quality and 
completeness of the data entry at the practices (18). All relevant gout related 
consultations or prescription for colchicine or allopurinol will be identified using 
search techniques based on Read codes and free text entries. Such searches have 
already been developed and successfully applied for foot and knee-related 
consultations in the Centre’s cohorts (19-21).  Full medical records of the consenting 
participants will be accessed for information regarding co-morbidities, other 
musculoskeletal problems, repeat consultations in primary care for gout (clinician 
recorded diagnosis mapped to standard Read code morbidity codes), prescription 
patterns and referral to secondary care. All sensitive data (name, contact details) will 
be removed from the medical records and the consultation data will be linked to the 
survey data by unique survey identifier. 
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Phase 3: Qualitative focus group interviews 
Phase 3 will consist of exploratory qualitative focus group interviews to investigate 
the previously unobserved factors that patients perceive as important outcomes of 
their gout treatment. By using an inductive qualitative strategy we hope to cover 
aspects of patient experience of gout treatment not considered previously.  Focus 
groups will encourage participants to discuss and share their individual experiences, 
thereby producing a more comprehensive and unconstrained account of patients’ 
perceptions, thoughts and beliefs about the treatment of gout.  In addition the group 
dynamics will encourage participants to question and reflect on each other’s 
responses, hence reducing interruption from the moderator.  
Choice of participants 
Drawing on the expertise of the research team a purposive sampling framework will 
be developed to identify participants encompassing a broad range of demographic 
and disease characteristics from the prospective observational cohort of gout 
patients. A sub-sample of 20 participants will be invited to one of four focus group 
interviews (each group consisting of 5 participants) initially. The group interviews will 
be held at the ARUKPCC or at the GP practices if facilities to do so are available.  
Participants will be sent a letter of invitation, and PIS outlining the details of the 
interview process and reimbursement for their travel to the centre (or GP practice as 
appropriate), including if necessary, pre-paid taxi. Participants will be asked to return 
a form (sent with the letter of invitation) to the ARUKPCC using a pre-paid return 
envelope, if they are interested in taking part in order to book an appointment.  Non-
responders to this initial invitation letter will be sent a reminder invitation 
approximately two weeks later.  Those willing to take part in the study will be booked 
into the next convenient interview group. Postal confirmation of the appointment will 
be made by letter and then by a reminder postcard shortly prior to the appointment. 
The postcard will be mailed in an envelope to maintain confidentiality about the 
nature of the appointment. Prior to commencing the interview, the procedures 
outlined in the PIS (for focus group interview) will be discussed with each 
participant. Participants will be given the opportunity to ask questions.  Written 
informed consent to take part in the study will be obtained from all participants.  
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Interview schedule 
The key question of interest in the interview schedule will be: 
“What do you expect your gout treatment to achieve or improve?” 
If prompts are needed the moderator can also ask about the following: 
 Satisfaction with treatments and their effectiveness   
 Subjective symptoms that describe patients’ perception of ill health in the 
context of their overall life situation, both physical and psycho-social 
Finally the moderator will provide a closing summary, invite any additional points for 
discussion and clarify any misinterpretations should they arise.   
Analysis 
The interviews will be carried out by a single moderator who has specific training of 
qualitative research methods with a particular emphasis on focus groups.  The 
interviews will be tape recorded and transcribed verbatim.  Data analysis will be 
conducted using thematic analysis. The moderator will read the data transcripts 
carefully and highlight discreet words and sentences that form the basis of key 
concepts and codes relevant to aspects of gout treatment.  All patient responses will 
be categorised by concepts (or codes) into provisional themes and reviewed across 
patients for each focus group.  To enhance the scientific rigour a second researcher 
will analyse the transcripts to identify the emerging concepts and themes.  It is likely 
that a second researcher from a different background will identify different concepts 
and themes.  A discussion between the two researchers will help to clarify and 
consolidate themes and concepts.   
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Phase 4, 5, 6 and 7: Follow-up at 6, 12, 24 and 36 months 
Follow-up surveys will be mailed at 6, 12, 24 and 36 months to all participants in 
phase 1 who consented to further contact.  The focus of follow-up will be clinical 
(pain/disability severity) change and possible determinants of this.  Those 
participants who agree to further contact at baseline (phase 1) will be mailed a 
further questionnaire at each follow-up stage.  In addition to information about 
clinical change, the questionnaire will also include repeat measures of lifestyle, 
general health (including generic measures of physical function), psycho-social 
factors, co-morbidity and questions concerning the presence, duration, nature, 
severity, and impact of gout pain. Non-responders to the questionnaire will be sent a 
reminder postcard after two weeks. Those who do not respond to the reminder 
postcard will be sent a repeat questionnaire, PIS and a further covering letter four 
weeks after the initial mailing.  The Primary Care Research Network team members 
will screen the mailing lists (prior to mailing) for patient deaths and departures from 
the practice to ensure that patients are not inappropriately contacted.  The study 
procedure is summarised in a flow chart in Appendix 2.   
Sample size 
Disease specific HRQOL scores will be recorded using the Gout Impact Scale at 
baseline, 6, 12, 24 and 36 months. In order to use the information recorded at all 
five points, a sample size of 882 would allow a smallest meaningful difference in 
HRQOL of 0.2 standard deviation units to be detected between two groups (441 
subjects per group) defined in terms of frequency of gout attacks (<2 attacks, ≥2 
attacks per year) using a linear mixed model (significance 0.05, power 90%, 
autocorrelation 0.8) (22).  Allowing for 70% response at baseline and 30% drop out 
over the follow-up period would require 1800 people with gout to be contacted at 
baseline. 
Statistical analysis 
Data from the self completed questionnaire and general practice medical records 
will be analysed as follows: 
 Descriptive account of flow of participants: eligible, mailed, responded, 
consented and followed up 
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 Age, gender and neighbourhood deprivation scores will be compared 
between baseline responders and non responders. 
 Simple descriptive statistics will be used to describe the baseline 
characteristics of the study population, for example demographics, 
anthropometrics, gout duration, gout attack frequency, physical function, 
psycho-social factors, co-morbidities, musculoskeletal pain, chronic foot 
problems (foot pain presence, location, related disability; hallux valgus) etc.  
The prevalence of poor HRQoL (%, 95% confidence interval) will be 
calculated for the study population and then compared between sub-groups 
defined according to age, gender, self-reported BMI and socio-economic 
status. Continuous variables will be compared using students’ t-tests and 
categorical variables using chi-squared tests.   
 Crude (unadjusted) odds ratio between poor HRQoL and potentially 
associated variables at baseline such as gout characteristics (frequency of 
gout attacks, disease duration), chronic foot problems (pain, hallux valgus), 
co-morbidities (hypertension, hyperlipidaemia, diabetes mellitus, renal 
disease, vascular disease, musculoskeletal pain), gout treatment (allopurinol) 
and psycho-social factors (anxiety, depression) will be calculated with 95% 
confidence intervals.  Significant variables identified in univariate analysis will 
then be entered into a multiple logistic regression model with poor HRQoL as 
the dependent variable. 
 Cox proportional hazards regression will be used to calculate relative risk 
(RR) (95% confidence interval) for factors predicting poor HRQoL and chronic 
foot problems prospectively over three years.   
 Amongst those people free of chronic foot problems (foot pain presence, 
location, related disability; hallux valgus) at baseline, the frequency of onset 
of chronic foot problems at 3 years will be described.   
 Amongst those people with chronic foot problems at baseline, the frequency 
of persistence and progression of those problems (foot pain presence, 
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spread, severity, associated disability; hallux valgus) at 3 years will be 
described.   
 Imputation techniques will be used to account for missing data or loss to 
follow up. 
565





Study Protocol, version 1.0, dated 15/02/12 
 
Conceptual domain Operational definition Empirical measure Number of 
items  
Time point 
Section A: About Gout 
Gout frequency No. of attacks in the last 12 months/since 
last contact 
Numerical rating scale 0-≥5 1 All 
Age at diagnosis Age in years Numerical free text box 1 BL 
Acute attack of gout  Acute episode at time of questionnaire Yes/ No 1 All 
Allopurinol Reported use of allopurinol 
Current daily dose of allopurinol 
Yes/No 





Section B: How gout affects your   life 
Gout concern, wellbeing, productivity, 
convenience and satisfaction 
Gout Impact Scale (6) 5-item Likert scale 18 All 
Illness perception Illness perception questionnaire (23) 5-item Likert scale 4 BL, 12 months, 36 
months 
Section C: General Health 
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Physical function SF36 Physical function sub-scale (PF10) 
(24) 
Health Assessment Questionnaire 
Disability Index (25) 
3-item Likert scale 
 







Co-morbidities Diabetes mellitus, Renal failure and 
calculi, CVA and TIA, IHD, 
hyperlipidaemia 
Yes / No 9 BL 
Section D: How you feel 
Anxiety and depression Patient health questionnaire (PHQ 9) (26) 
Generalised anxiety disorder 
questionnaire (GAD) (27) 
4 point Likert scale 16 BL, 12 months, 36 
months 
Section E: Foot and other joint problems 
Hallux valgus Self-completed line drawings (28) 5 line-drawings for each foot depicting 
increasing severity of hallux valgus 
2 BL, 12 months, 36 
months 
Pain Pain in the hands, hips, knees and feet in 
the last year 









BL, 12 months, 36 
months  
 
BL, 12 months, 36 
months 
Foot pain Foot pain, aching, stiffness in last month 
(31) 
Frequency on 5-point Likert scale 1 BL, 12 months, 36 
months 
Foot pain location Location of foot pain in last four weeks Self-completed foot manikin (32) 1 BL, 12 months, 36 
months 
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Foot function Manchester Foot Pain and Disability Index 
(33) 
Frequency on 3-point likert scale 17 BL, 12 months, 36 
months 
Consultation for foot problems Consultation with GP, physiotherapy, 
podiatry, chiropody since last 12 
months/since last contact 
Yes/No 4 BL, 12 months, 36 
months 
Section F: Work 
Occupational characteristics Current employment status 
Work absence during last 6 months due 
to joint/back problems 













BL, 12 months, 36 
months  
BL, 12 months, 36 
months  
 
BL, 12 months, 36 
months 
Section G: Demographic/socioeconomic characteristics 
Date of birth and gender Date of birth and gender Date of birth, male/female 2 BL 
Anthropometric characteristics Height 
Weight 
Metres or feet/inches 















Adequacy of income Adequacy of income 4-response options 1 BL 
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Education Higher education Yes/No 1 BL 
Ethnicity Ethnicity 6-response options 1 BL 
Life-style-characteristics Frequency of alcohol consumption 


























FLOWCHART OF STUDY PROCEDURE 
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Phase 2: Consent for 
medical record review  
Phase 3: Group interview with qualitative researcher 
Losses to follow-up 
Phase 4: Mailed 6-month Follow-up Survey 
Losses to follow-up 
Phase 5: Mailed 12-month Follow-up Survey 
Phase 6: Mailed 24-month Follow-up Survey 
Phase 7: Mailed 36-month Follow-up Survey 
Losses to follow-up 
Consent for further contact 
Phase 1: Mailed baseline Survey questionnaire 
Respondents to baseline Survey questionnaire 
All adults aged 18 years and over registered with30 
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NRES Committee North West - Liverpool East 
HRA NRES Centre North West  
Barlow House 
3rd Floor 




Telephone: 0161 625 7832  
Facsimile: 0161 625 7299 
30 April 2012 
 
Dr Edward Roddy 
Clinical Senior Lecturer in Rheumatology/ Honorary Consultant Rheumatologist 
Keele University 






Dear Dr Roddy 
 
Study title: Prospective observational cohort study of health related 
quality of life and chronic foot problems and their 
determinants in gout.   
REC reference: 12/NW/0297 
Protocol number: Protocol Number 1.0 
 
The Research Ethics Committee reviewed the above application at the meeting held on 19 




The Committee welcomed you both to the meeting and thanked you for what they had found 
to be a very well-written study. 
 
The Committee firstly asked why this study had not been submitted through the 
Proportionate Review service.  Neither of you knew the reason. 
 
The Committee had noted that in the Participant Information Sheet it was stated that 
questionnaires would be kept for 20 years and suggested that they be destroyed at the end 
of the study.  You both agreed. 
 
The Committee felt that there was a possibility that participants could be distressed and 
asked how this would be managed.  Dr Chandratre explained that it is not intended that the 
participants would be distressed but if they were she would use her training to manage the 
situation.  She would offer the participant the chance to take a break and step outside the 
room.  She would ask if they still wanted their data to be included and would remove it if not.  
If the distress was longer term she would suggest they contact their GP.  You emphasised 
that the questionnaire is not particularly likely to distress the participant.   
 
The Committee made reference to question 1.i. in section D of the Gout Study Questionnaire 
which asks how often a person has had „thoughts that you would be better off dead or of 
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hurting yourself in some way.‟  The Committee felt that questions such as this would 
potentially distress participants.  You explained that the questionnaire is validated and this is 
just a single question. 
 
The Committee suggested that questions such as this may potentially trigger pre-existing 
distress.  It was suggested that contact details for an alternative source of support such as a 
support group or charity were given.  You both agreed. 
 
The Committee asked about the GP practices to be involved in the study and how they 
would be notified as they had not seen a letter included with the application.  You explained 
that the GP practices are already signed up to the research network. 
 
The Committee asked if they would be including participants on the new gout drug 
Febuxostat.  You explained that they would not.  The prescription rate for this drug is very 
low. 
 
The members of the Committee present gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” below).  
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation‟s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
The Committee gave a favourable opinion of the application (with additional conditions as 
follows):  
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 Written clarification that questionnaires and tapes would be destroyed at the end of 
the study and not after 20 years should be provided.  This should be amended on 
page 2 of the Patient Information Sheets (questionnaires and interviews). 
 A section should be included in the Patient Information Sheet (questionnaires) about 
the risks of participating in the study.  Information should be included in this section 
about the possibility of becoming distressed during the study and what should be 
done in this situation.  Information should be included about support groups or 
charities that could be contacted if available. 
 The location of the interview should be given in the Patient Information Sheet 
(interviews). 
 It should be made clear in the Patient Information Sheet (interviews) that if distressed 
the participant could leave the interview.   
 The contact details for someone who could be contacted in the event of distress 
should also be given at the end of the questionnaire. 
 The Consent Form should include the following standard paragraph: „I understand 
that my medical notes and data collected during the study may be looked at by 
individuals from regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals to have access 
to the records‟. 
 
It is responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
You should notify the REC in writing once all conditions have been met (except for 
site approvals from host organisations) and provide copies of any revised 
documentation with updated version numbers. Confirmation should also be provided 




The documents reviewed and approved at the meeting were: 
  
Document    Version    Date    
Covering Letter from Edward Roddy  29 March 2012  
REC application: 89315/309525/1/664    02 April 2012  
Protocol  1.0  15 February 2012  
Investigator CV Dr Edward Roddy  29 March 2012  
Investigator CV Dr Priyanka Chandtratre  29 March 2012  
Investigator CV Professor Christian Mallen  05 April 2012  
Investigator CV Jane Crompton Richardson     
Letter from Sponsor from Rhian Hughes    02 March 2012  
Letter from Statistician from Dr Sara Muller  16 February 2012  
Peer Review Report- Outcome letter and revisions made after 
initial review 
 24 February 2012  
Letter to REC from Peer Review Committee from Professor 
PMS O'Brien 
 24 February 2012  
GP Information Leaflet  1.0  15 February 2012  
Letter of invitation to participant: Focus group interview 1.0  15 February 2012  
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appointment letter 
Letter of invitation to participant: invitation letter sent regarding 
the focus group interview 
  
Participant Information Sheet: for gout interview  1.0  15 February 2012  
Participant Information Sheet: for the gout study  1.0  15 February 2012  
Participant Consent Form: focus group interview  1.0  15 February 2012  
Two week reminder letter for focus group interviews   1.0  15 February 2012  
Covering letter sent with baseline questionnaire booklet 1.0 15 February 2012 
Covering letter to be sent with 6 months follow up 
questionnaire booklet  
1.0  15 February 2012  
Covering letter to be sent with 12 months follow up 
questionnaire booklet  
1.0  15 February 2012  
Covering letter to be sent with 24 months follow up 
questionnaire booklet  
1.0  15 February 2012  
Covering letter to be sent with 36 months follow up 
questionnaire booklet  
1.0  15 February 2012 
Two week reminder postcard 1.0 15 February 2012 
Two week reminder postcard sent after baseline questionnaire  1.0  15 February 2012  
Reminder letter sent with repeat Questionnaire at week 4 1.0 15 February 2012 
Reminder letter to be sent with repeat 6 months Questionnaire 1.0  15 February 2012  
Reminder letter to be sent with repeat 12 months 
Questionnaire 
1.0  15 February 2012  
Reminder letter to be sent with repeat 2 years Questionnaire 1.0  15 February 2012  
Reminder letter to be sent with repeat 3 years Questionnaire 1.0  15 February 2012  
Focus Group reminder postcard 1.0 15 February 2012 
Gout Study Questionnaire- baseline questionnaire booklet  1.0  15 February 2012  
Gout Study Questionnaire- 6 months follow up questionnaire 
booklet  
1.0  15 February 2012  
Gout Study Questionnaire- 12 months follow up questionnaire 
booklet  
1.0  15 February 2012  
Gout Study Questionnaire- 2 years follow up questionnaire 
booklet  
1.0  15 February 2012  
Gout Study Questionnaire- 3 years follow up questionnaire 
booklet  
1.0  15 February 2012  
Evidence of insurance or indemnity from George Smith  21 July 2011  
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 




Revised Approved docs. Table 2012.06.27  
A Research Ethics Committee established by the Health Research Authority 
    




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 




You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
12/NW/0297 Please quote this number on all correspondence 
 






On behalf of 
Mrs Jean Harkin 
Chair 
 
Email:     helen.penistone@northwest.nhs.uk 
 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
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Copy to: Dr Priyanka Chandratre  












Mrs Pam Devall  
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NRES Committee North West - Liverpool East 
 
Attendance at Committee meeting on 19 April 2012 
 
  
Committee Members:  
 
Name   Profession   Present    Notes    
Mr John Bridson  Clinical Ethicist  Yes    
Dr Zoe Edwards  Clinical Psychologist  Yes    
Mrs Jean Harkin  Chair / Solicitor  Yes    
Mrs Maureen Hendry  Pharmacist  Yes    
Mrs Glenys J Hunt  Alternate Vice Chair / 
Solicitor  
Yes    
Mr Chris Irving  Biomedical Scientist  Yes    
Professor Ebrahim Khalil 
Naderali  
Professor of Human 
Physiology  
Yes    
Mr Alex Newgrosh  Quality Assurance 
Manager  
Yes    
Professor Neil Pender  Professor of 
Orthodontics  
Yes    
Miss Helen Penistone  Co-ordinator  Yes    
Mrs Jean Pownceby  Lay Member  Yes    
Dr Richard Sarginson  Consultant 
(Anaesthesia/PICU)  
Yes    
Ms Karen  Tripp  Research Governance 
Administrator  
Yes    












To,        8th May 2012 
Mrs Jean Harkin 
Chair of the NRES Committee North West – Liverpool East 
HRA NRES Centre North West 
Barlow House 
3rd Floor 
4 Minshull Street 
Manchester M1 3DZ.       Reference: 12/NW/0297 
 
Re: Prospective observational study of health related quality of life and 
chronic foot problems and their determinants in gout.   
 
Dear Mrs Harkin, 
Thank you for the comments provided by the 12/NW/0297 Research Ethics 
Committee (REC) which we read with great interest.  We thank the panel members 
for the suggestions made.  We have tried to address these issues as outlined below.   
 
Written clarification that questionnaires and tapes would be destroyed at the 
end of the study and not after 20 years should be provided. This should be 
amended on page 2 of the Patient Information Sheets (questionnaires and 
interviews).  
In keeping with the Medical Research Council’s (MRC) policy of data storage, as 
outlined in section 7.1.2 of the ‘Personal Information in Medical Research- Medical 
Research Council Ethics Series’, we plan to store anonymised data in the form of 
questionnaires and digitalised audio data (from Focus Group Interviews) along with 
the transcripts for twenty years.  This is an acceptable length of time for data storage 
as per the MRC policy; 
“MRC would expect that research records relating to clinical or public health studies 
should be maintained for twenty years, to allow adequate time for review, 
reappraisal, or further research, and to allow any concerns about the conduct or 
consequences of the work to be resolved”   
MRC Guidance on Personal Information in Medical Research 
http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC002452 
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 Any identifiable personal information such as the participant’ s name and address 
will however be destroyed at the end of the study period, using methods approved by 
Keele University, such as deletion of electronic records or shredding of paper 
records and subsequent disposal using the confidential waste system.  This will 
ensure that personal data will not be stored for longer than is necessary (Data 
Protection Act 1998 (DPA) - Schedule 1, Part 1.  Research involving the NHS – 




The above information has been made explicit on page 2 of the Patient Information 
Sheet for the Questionnaires and the Focus group interview (version 2.0 dated 8th 
May 2012). 
 
A section should be included in the Patient Information Sheet (questionnaires) 
about the risks of participating in the study. Information should be included in 
this section about the possibility of becoming distressed during the study and 
what should be done in this situation. Information should be included about 
support groups or charities that could be contacted if available  
The nature of the questionnaire is not meant to be distressing, with anxiety and 
depression being assessed through validated questionnaires such as the PHQ9 in a 
target sample of participants with gout. However the small possibility of becoming 
distressed due to any of the questions has been made explicit in the Patient 
Information Sheet for the Questionnaires (The Gout Study Participant Information 
Sheet Version 2.0, dated 08/05/12).  If a participant contacts us reporting that the 
questionnaires evoked unpleasant memories or thoughts which may appear to be a 
risk to either the participant themselves or others, we will inform the participant’s 
General Practitioner (GP) as soon as possible. The participants will also be 
encouraged to contact their GP themselves should they feel distressed in any way 
as a consequence of completing the questionnaires.   Taking on board the advice 
provided by the REC committee we have also included the contact details of NHS 
mental health support groups (relevant to the areas of participant recruitment) which 
do not require referral from a healthcare practitioner.  All calls are free (call back also 
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available), confidential and support is provided by trained staff. For example, on 
average around 18000 calls per year are taken by the Staffordshire helpline and the 
team support approximately 60 potential suicide calls per month.   
 
Mental Health Helpline Staffordshire (Brighter Futures) 
0808 800 2234  
Mental Health Helpline Shropshire 
0800 195 1700  
Mental Health Helpline Wolverhampton  
0800 387034 
 
The location of the interview should be given in the Patient Information Sheet 
(interviews).  
The Gout Study Participant Information Sheet for Gout Interview Version 2.0 dated 
08/05/12 has been updated with information regarding the location of the Focus 
group interviews either at the Arthritis Research UK Primary Care Centre or at the 
GP Surgery if appropriate.   
 
It should be made clear in the Patient Information Sheet (interviews) that if 
distressed the participant could leave the interview.  
The Gout Study Participant Information Sheet for Gout Interview Version 1.0 dated 
15/02/12 states 
 “During the interview, you can choose not to answer questions, or to end the 
interview at any time, and for any reason.  If an interview topic brings back unhappy 
memories or distressing thoughts that you do not wish to discuss, the topic will not 
be followed up again during the interview”   
 
Following advice from the REC committee we have also added the following 
statement to clarify that by ending the interview the participant is also free to leave 
the place where the interview is being held; 
“You will also be offered the option of leaving the place where the interview is being 
held should you wish to do so”.   
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The contact details for someone who could be contacted in the event of 
distress should also be given at the end of the questionnaire.  
Contact details of mental health helplines as listed previously have been added to 
the Gout Study Questionnaire booklets at baseline, 6 months, 12 months, 2 years 
and 3 Years (all Version 2.0 dated 08/05/12).     
 
The Consent Form should include the following standard paragraph: ‘I 
understand that my medical notes and data collected during the study may be 
looked at by individuals from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to the records’.  
The consent form at the end of ‘The Gout Study - Baseline Questionnaire booklet 
Version 2.0, dated 08/05/12’ has been updated with the above paragraph insertion.   
 
Yours sincerely  
 
Dr Edward Roddy  
Clinical Senior Lecturer in Rheumatology / Honorary Consultant Rheumatologist  
Arthritis Research UK Primary Care Centre  
Primary Care Sciences  
Keele University  
Staffordshire  
ST5 5BG  
Tel:    01782 734715  
e.roddy@cphc.keele.ac.uk 
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Appendix 18: Testing for normal distribution of frequency of attacks data
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Appendix 19: Graphical representation of tests for normal distribution of 
HRQOL measures
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